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Abstract
Hyperglycaemia and hyperlipidaemia are the main causes of diabetes and obesityassociated complications. Increased oxidative stress, inflammatory responses and
altered energy metabolism have been associated with hyperglycaemia and
hyperlipidaemia. The concept of ‘glucolipotoxicity’ has arisen from the combination
of the deleterious effects of the chronic elevation of levels of glucose and fatty acids
on pancreatic β-cells’ function and/or survival. The synergistic effect of both
nutrients exacerbates β-cells’ dysfunction over time and creates a vicious cycle of
impaired insulin secretion and metabolic disturbances. Though numerous studies
have been conducted in this field, the exact molecular mechanisms and causative
factors still need to be established. The aim of the present work is to elucidate the
molecular mechanisms of altered cell signalling, oxidative and metabolic stress, and
inflammatory/antioxidant responses in the presence of high concentrations of
glucose/fatty acids in a cell-culture system using an insulin-secreting pancreatic βcell line (Rin-5F) and to study the effect of the antioxidant N-acetylcysteine (NAC)
on β-cell toxicity. In our study, we investigated the molecular mechanism of
cytotoxicity due to high glucose concentration (up to 25mM) and high saturated fatty
acid concentration (up to 0.3mM palmitic acid) on Rin-5F cells. In this regard,
initially, we investigated the effects of streptozotocin (STZ), a known β-cell toxin
that is structurally related to glucose, to identify specific molecular and metabolic
targets affected in pancreatic β-cells. Furthermore, we aim to elucidate the
cytoprotective effects of NAC on β-cell toxicity induced by STZ/high glucose/high
palmitic acid.
Our results show that the cellular and molecular mechanisms of β-cell toxicity are

viii
mediated by increased oxidative stress, imbalance of redox homeostasis, disruption
of mitochondrial bioenergetics and alterations in cell signalling. On the other hand,
NAC treatment attenuates β-cell cytotoxicity, apoptosis and mitochondrial damage
associated with oxidative stress.
The use of an in-vitro cell-culture model in this study suggests the cellular and
molecular mechanism(s) of β-cell toxicity without the involvement of multiple
physiological factors that would be seen in vivo, which might contribute to the
disease progression.
Keywords: Glucolipotoxicity, Rin-5F, streptozotocin, oxidative stress, mitochondria,
N-acetylcysteine.
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)Title and Abstract (in Arabic

تأثير ارتفاع نسبة الجلوكوز و الدهون على سمية الخاليا ،الجهد التأكسدي و تشوير
الخاليا في خاليا البنكرياس  :Rin-5F cellsتثبيطها بواسطة N-acetylcystiene
الملخص
ارتفاع نسبة السكر و الدهون في الدم هي من األسباب الرئيسية لمرض السكري والسمنة و مضاعافاتها .وقد
ارتبطت زيادة اإلجهاد التأكسدي ،االستجابات االلتهابية وتغير الطاقة األيضية مع ارتفاع السكر و الدهون في
الدم .نشأ مفهوم " "Glucolipotoxicityمن الجمع بين اآلثار الضارة لالرتفاع المزمن لمستويات الجلوكوز
والدهون في وظائف خاليا البيتا في البنكرياس .ويزيد التأثير للمغذيات من ضعف خاليا البيتا مع مرور الوقت
ويخلق حلقة مفرغة من قلة إفراز األنسولين و االضطرابات االستقالبية .على الرغم من إجراء العديد من
الدراسات في هذا المجال ،لكن ال تزال هناك حاجة إلى تحديد اآلليات الجزيئية الدقيقة والعوامل المسببة .الهدف
من هذا العمل هو توضيح اآلليات الجزيئية لإلشارات الخلوية ،واإلجهاد التأكسدي و االستقالبي ،و االستجابات
االلتهابية/المضادة لألكسدة في وجود نسبة مرتفعة من الجلوكوز/األحماض الدهنية في أنظمة زراعة األنسجة
الخلوية و ذلك باستخدام خاليا البنكرياس ) (Rin-5Fالتي تفرز األنسولين و دراسة تأثير مضادات األكسدة،
)N-acetylcystein (NACعلى سمية الخاليا .في دراستنا ،قمنا بالتحري عن اآللية الجزيئية الرتفاع
الجلوكوز (تصل إلى  )25 mMو زيادة األحماض الدهنية المشبعة (تصل إلى , 3.0 mMحمض بالمتيك) التي
تؤدي الى السمية الخلوية لخاليا  .Rin-5Fفي هذا الصدد ،قمنا في بادئ األمر بالتحري عن تأثيرات
الستربتوزوتوسين ) , (STZوهو قاتل لخاليا البيتا في البنكرياس و يرتبط ارتبا ً
طا هيكليًا بالجلوكوز ,لتحديد
االقسام الجزيئية وااليضية المتضررة في خاليا البيتا في البنكرياس .باالضافة إلى ذلك سيتم التحقق من آلية
اآلثار الوقائية لمضادة االكسدة ) N-acetyl cysteine (NACلتوضيح آلية الحماية الخلوية في خاليا البيتا
في البنكرياس.
أظهرت نتائجنا أن اآلليات الخلوية والجزيئية لسمية خاليا البيتا تنتج من زيادة اإلجهاد التأكسدي ،اختالل توازن
األكسدة ،تعطيل الطاقة الحيوية للميتوكندريا وتغيي ر في تشوير الخاليا .من ناحية أخرى ،خفف  NACمن تسمم
الخاليا البيتا ،وموت الخاليا المبرمج واألكسدة المرتبطة بأضرار الميتوكوندريا.
ان استخدام نموذج زراعة الخاليا في المختبر في هذه الدراسة يبرز اآللية الخلوية والجزيئية لسمية خاليا البيتا

x
دون تدخل العوامل الفيزيولوجية المتعددة في الجسم الحي ،والتي قد تسهم في تطور المرض.
مفاهيم البحث الرئيسية ,glucolipotoxicity, Rin-5F; streptozotocin, N-acetylcysteine :جهد
األكسدة ,الميتوكندريا.
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Chapter 1: Introduction
The pancreas is the vital organ that controls the whole-body metabolism. The
main functions of the pancreas are to produce exocrine enzymes to aid digestion and
endocrine hormones to regulate blood glucose. The pancreas orchestrates release of
endocrine hormones in response to nutrients, glucose, lipids and amino acids, along
with hormones and inflammatory signals. Pancreatic cells, especially insulinproducing β-cells, control nutrient breakdown and energy production. Moreover,
competent energy metabolism in pancreatic cells is essential for secretion of
hormones, in particular insulin and glucagon, that regulate the utilisation of glucose
and lipids throughout the body. Therefore, pancreatic metabolism plays a key role in
regulating energy homeostasis in the human body.
Energy production results largely from the oxidative metabolism of either
glucose or fatty acids. In addition, these molecules significantly contribute to tissue
building and disease development, particularly metabolic diseases and cancer [1–5].
The specific pathogenesis of these diseases remains unclear. However, the
deleterious effects of the chronic elevation of glucose and fatty acids levels have
been shown to have a significant role. Several hypotheses have been proposed,
including glucotoxicity and lipotoxicity [2,4,6,7] caused by chronic hyperglycaemia
and chronic dyslipidaemia, respectively. The concept of glucotoxicity [8] and
lipotoxicity [7] were first suggested by Unger and his team. Overstimulation of
glucose reduces β-cell function and insulin action by attenuation of insulin-mediated
glucose transport and impairment of glucose-induced insulin secretion, causing
hyperglycaemia, which subsequently leads to deterioration of β-cell function. In
addition, excessive exposure to high levels of fatty acids causes β-cell dysfunction,
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inhibits glucose-induced insulin secretion, and induces β-cell death by apoptosis [9].
The physiology of energy metabolism for glucose and fatty acids is briefly
summarized below in order to clarify the cellular and molecular mechanisms of
glucolipotoxicity.

1.1 Energy sources and metabolism
Living cells produce energy through the oxidation of organic substances, such
as glucose and fatty acids.
1.1.1 Glucose metabolism
Glucose metabolism is one of the central metabolic processes in the body that
produces energy and acts as a substrate for other metabolic pathways. There are three
main pathways associated with glucose metabolism: glycolysis, the tricarboxylic acid
cycle (the TCA or Krebs cycle) and the pentose phosphate pathway.
Glycolysis provides the substrates required for energy production via the
formation of adenosine triphosphate (ATP) by the breakdown of glucose into
pyruvate/lactate following glucose uptake by cells and glucose phosphorylation. In
normal cells, glucose is catabolised to pyruvate, which is later converted to acetylCoA and fuels the TCA cycle. Acetyl-CoA can serve as a substrate for fatty acid
synthesis. In the TCA cycle, acetyl-CoA subsequently forms citric acid, which is
then further metabolised to produce oxaloacetate through a series of reactions. The
TCA cycle generates nicotinamide adenine dinucleotide (NADH) and flavin adenine
dinucleotide (FADH2), which provide the mitochondrial respiratory chain with
electrons for energy production through oxidative phosphorylation reactions. Each
molecule of glucose can produce up to 36 ATP molecules. Glycolysis also provides a
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substrate for storage pathways of glycogenesis and lipogenesis [10]. Several studies
have shown the involvement of glycolysis in the development of diseases such as
cancer, diabetes and obesity [11–14].
The pentose phosphate pathway is a parallel route to glycolysis. It generates
nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate,
with the latter being the precursor for nucleotide synthesis. There are two distinct
phases within this pathway; the initial oxidative phase in which NADPH is
generated, and the non-oxidative synthesis of 5-carbon sugars (Figure 1).

Figure 1: Glucose metabolism.
Following uptake, glucose is converted to pyruvate which is laterally converted to
acetyl-CoA to fuel the citric acid or TCA cycle. In the TCA cycle, acetyl-CoA
subsequently forms citric acid which is then further metabolised to form oxaloacetate
through a series of reactions. The pentose phosphate pathway generates NADPH and
ribose-5-phosphate via two phases; the oxidative phase in which NADPH is
generated, and the non-oxidative synthesis of 5-carbon sugars. Modified from [15].
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1.1.2 Fatty acid metabolism
Fatty acids have a long hydrocarbon chain and a terminal carboxylate group.
They serve multiple physiological functions, but their main role is as fuel molecules.
Fatty acids enter cells via fatty acid protein transporters present on the cell surface.
Once inside a cell, fatty acyl-CoA synthase (FACS) adds a CoA group to a fatty acid,
forming long-chain acyl-CoA (LC-CoA). To enable fatty acid transportation across
the inner mitochondrial membrane, carnitine palmitoyltransferase-1 (CPT-1)
converts LC-CoA to long-chain acylcarnitine, and carnitine translocase (CAT)
facilitates the crossing of the fatty acid moiety through the inner mitochondrial
membrane via the exchange of long-chain acylcarnitine to carnitine. Consequently,
carnitine palmitoyltransferase-2 (CPT-2), which is present at the inner mitochondrial
membrane, converts long-chain acylcarnitine back to LC-CoA. LC-CoA then enters
the fatty acid β-oxidation pathway, resulting in the production of acetyl-CoA [16].
Fatty acid β-oxidation is the process of breaking down a LC-CoA molecule to acetylCoA molecules, which then enter the TCA cycle. The NADH and FADH2 generated
from the TCA cycle provide electrons to the electron transport chain for energy
production (Figure 2). Fatty acids provide a potent source of energy, for example the
oxidation of palmitate can generate 106 ATP molecules [17].
Another physiological role of fatty acids is as substrates for the synthesis of
signaling molecules and complex lipids. They are also ligands for membrane
receptors involved in cell signalling and nuclear receptors to mediate gene regulation
[2]. The toxic effect of free fatty acids (FFA) is dependent upon the length of the
carbon chains and numbers of double bonds. Studies have reported that the
accumulation of long-chain saturated fatty acids (LC-SFA), especially palmitate and
stearate, leads to cell dysfunction and induces cell death by triggering the production
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of reactive oxygen species (ROS) [18] and the induction of apoptosis [19,20].
Palmitate, stearate and oleate are physiologically the most abundant FFAs,
accounting for almost 70% to 80% of total plasma FFAs [21]. In contrast, lower
toxicity has been reported for the accumulation of long-chain monounsaturated fatty
acids (MUFAs), such as oleate and palmitoleate. In vitro studies have shown that
saturated fatty acids induce β-cell apoptosis, while unsaturated fatty acids are usually
cytoprotective [22,23]. Unsaturated fatty acids do not affect β-cell apoptosis; rather,
they promote β-cell proliferation at low glucose concentrations, counteracting the
negative effects of saturated fatty acids, as well as improving β-cell function [23].
Moreover, the combination of both saturated and unsaturated FFA demonstrate an
even lower cytotoxic effect, suggesting that MUFA can inhibit or promote the
detoxification of LC-SFA by altering their partitioning within cells [19,24,25]. It has
been reported that the supplementation of unsaturated fatty acids with saturated fatty
acids results in the sequestering of saturated fatty acids away from pathways leading
to cell death through the promotion of triglyceride accumulation [26].
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Figure 2: Fatty acid β-oxidation.
Fatty acids enter cell via fatty acid protein transporters present on the cell surface.
Once inside, FACS adds a CoA group to the fatty acid, before CPT-1 converts the
long-chain acyl-CoA to long-chain acylcarnitine. The fatty acid moiety is transported
by CAT across the inner mitochondrial membrane, whereupon CPT-2 then converts
long-chain acylcarnitine back to long-chain acyl-CoA. Long-chain acyl-CoA can
then enter the fatty acid β-oxidation pathway, resulting in the production of one
acetyl-CoA from each cycle of β-oxidation, which then enters the TCA cycle. The
NADH and FADH2 produced by both β-oxidation and the TCA cycle are used by the
electron transport chain to produce ATP. Adapted from [16].

1.2 Glucolipotoxicity
The concept of glucolipotoxicity has arisen from the combination of the
deleterious effects of the chronic elevation of levels of glucose and fatty acids on
pancreatic β-cell function and/or survival [27]. The synergistic effect of this
combination of both nutrients exacerbates β-cell dysfunction over time and creates a
vicious cycle by which impairment of insulin secretion worsens the metabolic
disturbances [27,28]. Studies have shown that elevated glucose levels augment the
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effect of FFA-induced cell death, because high glucose concentration inhibits fat
oxidation, and consequently lipid detoxification [22]. Glucolipotoxicity has also been
implicated in metabolic syndrome and associated complications in diabetes.
1.2.1 Mechanisms of glucolipotoxicity
Glucose is the key element that determines fatty acid oxidation in β-cells, as
first reported by Prentki and Corkey [27]. At normal glucose levels, fatty acids are
transported into the mitochondria via CPT-1 and undergo β-oxidation to generate
acetyl-CoA, which serves as a substrate for the TCA cycle. Fatty acid metabolism
generates reducing equivalents used by the electron transport chain for ATP
synthesis [29]. When the concentrations of glucose and fatty acids are both
increased, glucose metabolism in the TCA cycle generates molecules that perform
cataplerotic signals, such as citrate. This leads to the formation of malonyl-CoA
within the cytosol. Malonyl-CoA is a known inhibitor of CPT-1 activity, which
blocks fatty acid oxidation and results in the accumulation of LC-CoA esters in the
cytosol [27]. The accumulation of metabolites derived from fatty acid esterification
in turn inhibits glucose-induced insulin gene expression and insulin secretion [30].
Higher glucose levels direct fatty acid partitioning away from oxidation into
esterification, and activate the expression of genes involved in lipogenesis [31].
Numerous studies have revealed the apoptotic effect of fatty acids in β-cells in the
presence of high amounts of glucose. Work to understand the molecular mechanisms
of glucolipotoxicity is a promising approach when aiming to treat metabolic diseases
such as insulin resistance, obesity, type 2 diabetes mellitus (T2DM).
The mechanism of glucolipotoxicity involves several transcription factors, and
is, at least in part, mediated by the generation of chronic oxidative stress. Three such
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mechanisms are described below:
1.2.1.1 Mitochondrial dysfunction due to glucolipotoxicity
Mitochondria are energy-producing organelles. They are the main sites of lipid
and glucose metabolism, and the major source of ROS, by-products of the
mitochondrial electron transport chain. ROS can react with multiple cellular
components, such as proteins, lipids and nucleic acids, leading to reversible or
irreversible oxidative modifications.
Hyperglycaemia causes an increase in glucose metabolism and thus leads to the
overproduction of NADH and FADH2, which are used to generate ATP by the
mitochondrial electron transport chain [32]. Overproduction of NADH can produce a
steeper proton gradient within mitochondria, and this causes single electron transfer
to oxygen, leading to the formation of free radicals, particularly superoxide anions
[33]. The two main sites of superoxide production via the electron transport chain are
NADH dehydrogenase (ubiquinone oxidoreductase) in the area known as complex I,
and cytochrome c reductase in complex III [34].
Similarly, elevated levels of fatty acids increase the accumulation of LC-CoA
and stimulate ROS overproduction, which in turn inhibits insulin secretion and β-cell
function [28,35]. Prolonged exposure to FFA reduces the potential across the
mitochondrial membrane and causes overexpression of uncoupler protein-2 (UCP-2)
which consequently leads to a decrease in ATP production and insulin secretion [36].
Moreover, studies have shown that elevated amounts of glucose and FFA affect
mitochondria morphology and biogenesis, with mitochondria becoming smaller and
condensed [37], not containing enough space to maintain normal or excessive
metabolic needs. In addition, the same study reported elevated ROS levels, a
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disrupted membrane potential, and a reduction in the intra-mitochondrial calcium
concentration, leading to further mitochondrial dysfunction.
1.2.1.2 Polyol pathway - induced oxidative stress due to hyperglycaemia
Under

normal

physiological

conditions,

glucose

is

predominantly

phosphorylated into glucose 6-phosphate by hexokinase and enters the glycolytic
pathway. Only trace amounts of non-phosphorylated glucose (3%) enter the polyol
pathway [38]. Under hyperglycaemic conditions, glucose flux to the polyol pathway
increases by up to 35% [39,40].
There are two potential mechanisms by which the polyol pathway could
contribute to oxidative stress. Aldose reductase catalyses the reduction of glucose to
sorbitol using NADPH, but NADPH is essential for the generation of glutathione
(GSH) from the oxidized form glutathione disulphide (GSSG). In hyperglycaemia,
sorbitol overproduction reduces the availability of NADPH, which in turn reduces
GSH regeneration and increases nitric oxide synthase (NOS) activity, causing
increased oxidative stress [32]. Sorbitol dehydrogenase oxidises sorbitol to fructose,
requiring NADH as a cofactor [40,41]. Therefore, increased NADH may be used by
NADH oxidases to increase superoxide production in mitochondria (Figure 3) [42].
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Figure 3: Role of polyol pathway in hyperglycaemia-induced oxidation.
Excess glucose is shunted to the polyol pathway, where aldose reductase catalyses its
reduction to sorbitol using NADPH. Depletion of NADPH as a result of
hyperglycaemia impairs the production of GSH. Sorbitol is then converted to
fructose by sorbitol dehydrogenase which produces NADH, potentially leading to
increased ROS via NADH oxidase. Adapted from [43].

1.2.1.3 Advanced glycated end-products in hyperglycaemia
The intermediate metabolites of the glycolytic pathway and the polyol pathway
are more potent non-enzymatic glycation agents than glucose [44]. The end-products
of glycation contain ketone or aldehyde groups of reducing glucose bound to the free
amino groups of proteins, leading to the formation of Schiff bases without the
involvement of enzymes. An initial Schiff base undergoes rearrangement in order to
become a more stable ketoamine, called an Amadori's product. These products can
be degraded into a wide range of highly reactive carbonyl compounds, such as 3deoxy-glucosone, which can react with free amino groups to form intermediate
glycation products. A complex series of chemical rearrangements can produce
irreversible advanced glycated end-product (AGE) structures, which are yellowbrown in colour, fluorescent, and have a tendency to generate ROS and interact with
specific cell-surface receptors [45–47]. AGE-receptors play a critical role in the
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pathogenesis of diabetes [45,48]. AGEs have been implicated in the induction and
progression of various vascular diseases [46,49], diabetic neuropathy [50,51],
diabetic nephropathy [52,53] and diabetic retinopathy [54,55]. The precise
pathogenic role of these receptors in initiating diabetic complications is poorly
understood. Recent studies show that AGE-receptor binding can initiate important
signalling pathways involving the induction of oxidative stress cascades [56], which
increase proinflammatory signalling via nuclear factor kappa-light-chain-enhancer of
activated β-cells (NF-кB) [57]. Moreover, glycation can inactivate antioxidant
enzymes, impairing antioxidant defences, as observed with the glycation of
superoxide dismutase [58].
1.2.2 Effect of glucolipotoxicity in obesity
The World Health Organization (WHO) has defined obesity and being
overweight as abnormal or excessive fat accumulation that may impair health [59].
Obesity has become a global health epidemic, and the incidence of obesity is rising
progressively. However, in recent years this increase has been more noticeable in
children, and is occurring in both developed and developing countries [60]. Energy
imbalance between calorie intake and calories consumed is the fundamental cause of
obesity and overweight. The major co-morbidity conditions associated with obesity
include cardiovascular diseases, diabetes, musculoskeletal disorders (especially
osteoarthritis), and some cancers, including endometrial, breast, ovarian, prostate,
liver, gallbladder, kidney, and colon [59].
Obesity has been recognised as a major causative factor for insulin resistance
and is associated with diabetes [61]. This is due to the altered glucose homeostasis
via decreased glucose uptake by the muscle, altered lipogenesis, and increased
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glucose output by the liver. Studies have reported elevated levels of FFA in obese
patients as a consequence of the increased release of fatty acids from enlarged
adipose tissue, and a reduction in FFA plasma clearance [62–64].
The release of FFA is considered the key factor in the development of insulin
resistance. FFA inhibit insulin-stimulated glucose uptake in muscle through the
initial inhibition of glucose oxidation, transport and phosphorylation [65]. FFA also
produce low-grade inflammation in skeletal muscle, the liver and fat, which may
contribute to cardiovascular events [66]. In vivo studies have shown that elevated
levels of plasma FFA cause insulin resistance in human skeletal muscle through
increases in diacylglycerol (DAG) content, activation of protein kinase C (PKC) and
activation of the NF-κB pathway (Figure 4) [67]. Increased concentrations of
malonyl-CoA due to the presence of excess glucose increase FFA esterification and
decrease mitochondrial oxidation, which in turn enhance the formation of
triglyceride and DAG synthesis. DAG is a potent allosteric activator of PKC [68],
increasing its activation and subsequently causing insulin resistance through
activation of the NF-κB pathway. It has been shown in endothelial cells that an
elevated level of glucose results in the activation of the NF-κB pathway through PKC
[69]. Similarly, in vitro studies have shown that FFA-induced hepatic insulin
resistance is associated with increased activation of the NF-κB pathway and
increased expression of pro-inflammatory cytokines, like tumour necrosis factor
alpha (TNF-α) and interleukin 1-beta (IL-1β) [70]. Initially, low levels of IL-1β are
expressed and released in order to adapt to the increased metabolic stress; however,
prolonged elevation of glucose and FFA concentrations leads to the activation of
interleukin-1 receptor, type I (IL-1R), which further increases the levels of IL-1β via
an auto-stimulatory process, together with the production of IL-1-dependent
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cytokines and chemokines, the attraction of macrophages, apoptosis and impaired
insulin secretion (Figure 5) [71].

Figure 4: Insulin resistance in human muscle associated with DAG accumulation and
the activation of PKC and the NF-κB pathway.
Increases in amounts of plasma FFA elevate the cytosolic concentration of LC-CoA,
which in turn enhances glycerolipid triglyceride and diacylglycerol (TG, DAG)
synthesis, both by generating α-glycerophosphate and by enhancing the synthesis of
malonyl CoA, which inhibits fatty acid oxidation by inhibiting CPT-1. DAG is a
potent activator of PKC which activates the NF-κB pathway. Adapted from [67].
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Figure 5: Elevated levels of glucose and FFA increase expression of IL-1.
Initially, an increased amount of glucose and FFA results in the expression and
release of low levels of IL-1β. However, prolonged stimulation leads to the
activation of IL-1R, leading to a further increase in amounts of IL-1β and the
production of IL-1-dependent cyto- and chemokines. Adapted from [71].

1.2.3 Effect of glucolipotoxicity in cancer
Metabolic dysregulation has a detrimental impact on cancer aetiology [72]. The
reprogramming of metabolic processes, such as glycolysis and lipogenesis, is a
distinctive characteristic of cancer cells in order for the highly proliferative cells to
obtain sufficient energy [73–76]. Warburg first reported in the 1920s [77] that cancer
cells relied on glycolysis as a major bioenergetics source, independent of oxygen
availability. The basic characteristic of a tumour cell is increased glucose
consumption, which is linked to energy production from glycolysis. Hyperglycaemia
is commonly manifested in cancer patients, and high glucose levels activate various
signalling pathways that are involved in cancer cell proliferation, migration, invasion
and recurrence [78]. It is documented that diabetes plays a dominant role in the
development of solid organ malignancies [79,80]. Moreover, in addition to the
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changes to glucose metabolism, studies on human cancers have reported that FFA
turnover, oxidation and clearance is also increased [81,82].
The first study to determine lipid synthesis in neoplastic tissues was by Medes
et al. [83], who concluded that a tumour could utilise glucose and acetate for the
synthesis of fatty acid chains. However, this process was probably too slow to supply
the lipid needs of a rapidly growing tumour, so the tumour would obtain lipids from
the host. Later, several studies reported the up-regulation of the de novo synthesis of
fatty acids in tumour cells to satisfy the demand for lipids [84,85]. Furthermore, it
was shown that the inhibition of fatty acid biosynthesis repressed cancer growth [86].
Epidemiological evidence indicates an association between cancer incidence and
diabetes, as well as obesity and overweight. This suggests how increased amounts of
glucose and fatty acids have potentially deleterious effects in the development of
these diseases.
Over-nutrition promotes oxidation of glucose and fatty acids, leading to the
increased generation of electron donors in the mitochondrial electron transport chain
and therefore overproduction of mitochondrial ROS [87]. Subsequently, oxidative
DNA damage occurs, which is an initial step for carcinogenesis [88]. ROS
overproduction changes the cellular redox status, leading to alterations in the
activities of transcription factors, such as hypoxia-inducible factor 1-alpha (HIF1-α)
[89] and FOS–JUN [90], thereby stimulating cancer cell proliferation. ROS also
activate cancer cell proliferation through the regulation of the ERK-MAPK pathway
[91]. Activation of the NF-κB pathway has been reported to stimulate cell
proliferation in numerous cancer cell lines [92] whereas the inhibition of NF-κB
blocks cell proliferation [93]. The method of activation of NF-κB by ROS is not
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clear. However, mild oxidative stress can lead to modest NF-κB activation, while
extensive oxidative stress can inhibit NF-κB [94].
1.2.4 Effect of glucolipotoxicity in diabetes
Diabetes mellitus is a complex metabolic disorder that is characterised by high
levels of blood glucose (hyperglycaemia), the impairment of insulin secretion, and
insulin resistance [95]. As insulin is required for cellular glucose uptake in order to
convert it into energy, the ineffectiveness of insulin action or decreased production
causes hyperglycaemia. The number of diabetic patients has doubled over recent
decades, making this disease a global challenge. The WHO projects that diabetes will
be the seventh leading cause of death in 2030 [96]. In 2015, 415 million cases of
diabetes were reported worldwide, and in the same year five million deaths were
reported, with one person dying every six seconds from diabetes [97].
Hyperglycaemia is considered to be the main cause of diabetic complications. It has
been reported that obesity is linked to insulin resistance and type 2 diabetes mellitus
(T2DM) [98]. Normal pancreatic islets adapt their mechanisms in response to
increased metabolic load caused by obesity and insulin resistance, thereby increasing
β-cell mass through an increase in β-cell proliferation and neogenesis [99], as well as
by enhancing β-cell function [100]. However, as a result of genetic and
environmental factors that cause a progressive decline in β-cell function and survival,
β-cell adaptation eventually fails. Consequently, individuals develop impaired
glucose tolerance and then T2DM is established with reduced β-cell mass [98].
Although β-cell dysfunction is the suggested mechanism of T2DM, the main cause
of this disease remains unknown.
The molecular mechanisms underlying β-cell dysfunction are unclear.
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However, recent studies suggest that β-cell loss in T2DM can be attributed to
increased β-cell apoptosis [101,102]. This effect is due to endoplasmic reticulum
stress, facilitated by protein misfolding due to the accumulation of toxic islet amyloid
polypeptide oligomers [103] and mitochondrial dysfunction [104]. Moreover,
hyperglycaemia and hyperlipidaemia are widely known causes of enhanced ROS
generation and induced tissue injury [105–107], and oxidative stress is recognised as
the pathogenic mechanism in diabetic complications [33].
Once the primary pathogenesis of diabetes is established, which is potentially
linked

to

both

genetic

and

environmental

factors,

hyperglycaemia

and

hyperlipidaemia exert further destructive and/or toxic effects on β-cells [108].
Studies report that elevated levels of glucose and palmitate impair glucose-sensitive
insulin release and decrease insulin concentration. Furthermore, the deleterious
effects of glucose and FFA also disrupt the potential across islet cell mitochondrial
membranes [107] and decrease ATP production.
Raised levels of FFA decrease translocation of glucose transporter type 4
(GLUT4) to the plasma membrane in skeletal muscles, either directly, through
alterations to trafficking, fusion, or activity of GLUT4 [109], or indirectly, through
inducing alterations in insulin signalling. Increased levels of FFA metabolites, such
as DAG, fatty acyl-CoA and ceramides, enhance the phosphorylation of
serine/threonine sites and reduce the number of tyrosine phosphorylation sites
present on insulin receptor substrates (IRS-1 and IRS-2). This in turn reduces their
ability to activate phosphatidylinositide 3-kinase (PI 3-kinase) [110]. Taken together,
this alteration in the insulin signalling pathway diminishes glucose transport activity
and induces insulin resistance (Figure 6). Moreover, it has also been shown that
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increased amounts of glucose and FFA stimulate IL-1β secretion and the activation
of IL-1R. This stimulation in turn activates NF-кB and MAPK, leading to the
activation of the apoptotic pathway due to endoplasmic reticulum and mitochondrial
stress [111,112].
Studies report that insulin resistance and reduced glucose uptake by skeletal
muscle stimulates hepatic gluconeogenesis and enhances FFA release from adipose
tissue. Under these conditions, adipose tissue macrophages and Kupffer cells are
activated, and they express high levels of pro-inflammatory mediators, such as IL-1β,
TNFα and nitric oxide, while suppressing the production of IL-1R [113]. The
increased expression of IL-1R1 in β-cells make these cells more susceptible to the
effects of IL-1β than other cell types [114]. The ultimate results of increased insulin
resistance are elevated glucose and FFA levels, together with inflammatory
mediators that directly have toxic effects for β-cells (Figure 7).
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Figure 6: Mechanism of fatty acid-induced insulin resistance in human skeletal
muscle.
Increased delivery of fatty acids to muscles, or decreased fatty acid metabolism,
leads to an increase in fatty acid metabolites, such as diacylglycerol, fatty acyl-CoA,
and ceramides. These metabolites activate PKC, which in turn activates the
phosphorylation of serine/threonine sites on insulin receptor substrates (IRS-1 and
IRS-2) and inhibits the phosphorylation of tyrosine sites. Consequently, the ability of
the insulin receptor substrates to activate PI 3-kinase is reduced and glucose transport
activity is diminished. Adapted from [115].
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Figure 7: Insulin resistance damages β-cells and leads to autoimmune insulitis.
(A) In insulin sensitive individuals, insulin secretion induces the uptake of glucose
from the circulation by skeletal muscle and adipose tissue and diminishes the release
of FFA from adipose tissue as well as suppressing hepatic gluconeogenesis. In such
cases the expression of activated interleukin-1 receptor antagonist (IL1-Ra) and the
release of IL-1β are suppressed. (B) In contrast, insulin resistance reduces glucose
uptake, leads to unsuppressed hepatic gluconeogenesis, and enhances FFA release
from adipose tissue. Under these conditions, adipose tissue macrophages and Kupffer
cells are activated, expressing high levels of pro-inflammatory mediators, such as IL1β, TNFα, and nitric oxide, while suppressing production of IL-1R. The ultimate
effects of increased insulin resistance are the elevation of glucose and FFA levels and
of inflammatory mediators that are toxic to β-cells. Processes associated with insulin
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sensitivity are shown in blue; processes associated with insulin resistance are
indicated in red. The arrow weight indicates the relative flux through individual
pathways. Adapted from [113].
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1.3 Models for diabetes
1.3.1 In vivo models of diabetes
There are different animal models used to study diabetes, including:
1.3.1.1 Chemically induced models of diabetes
Two main diabetogenic agents are used to trigger diabetes: streptozotocin
(STZ) and alloxan. Both chemicals are glucose analogues and tend to accumulate in
the pancreas through glucose transporter type 2 (Glut2) [116]. The cytotoxic effect of
both diabetogenic agents is based on the generation of reactive oxygen species.
However, the source of their generation is different in the two cases [117].
Streptozotocin (STZ) is the chemical N-(Methylnitrosocarbamoyl)-α-Dglucosamine. It is a broad spectrum antibiotic derived from the bacterium
Streptomyces achromogenes [118]. It is a DNA alkylating agent and is often used as
an anti-bacterial as well as anti-cancer medicine [119,120]. However, it is not a
preferred drug for the treatment of cancers. This is due to genotoxic effects which
lead to drug resistance [121]. STZ is a glucose analogue that is selectively
accumulated in pancreatic beta cells via GLUT2 in the plasma membrane [122,123].
After entering the β-cells by this route, it causes DNA damage due to the DNA
alkylating activity of its methyl nitrosourea moiety [124,125]. This results in DNA
fragmentation [126]. Subsequently, the fragmented DNA activates poly (ADPribose) synthetase to repair DNA. Poly ADP-ribosylation leads to depletion of
cellular NAD+ and ATP [126,127]. The decreased ATP synthesis is demonstrated by
dephosphorylation which provides more substrate for xanthine oxidase, resulting in
the formation of hydrogen peroxide and hydroxyl radicals [117,128] causing
oxidative stress. Furthermore, the N-methyl-N-nitrosourea side chain can release
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nitric oxide [129,130] that inhibits aconitase activity, resulting in mitochondrial
dysfunction. STZ is diabetogenic due to its targeted GLUT2-dependent action in the
pancreatic β-cells. The exact mechanism of cytotoxicity is still not clear. However,
both apoptotic and necrotic cell death of β-cells have been reported. The cytotoxicity
of STZ is presumed to be mediated by ROS, reactive nitric oxide species (NO/RNS)
and induction of inflammatory responses [129,130].
STZ is widely used to induce experimental type-1 diabetes in rodent models.
Type-2 diabetes has been produced by nicotinamide pre-administration to STZ in
adult rats [131]. Nicotinamide as an antioxidant partially protects against the
cytotoxic action of STZ by scavenging the free radicals, thereby causing minor
damage to pancreatic cells and producing type-2 diabetes. Furthermore, type-2
diabetes has been induced in two-day-old neonatal Wistar rats by injecting 100
mg/kg of STZ either by intravenous or intraperitoneal injection [132].
STZ can be administered to rats to induce type-1 diabetes in two ways, either
using a single high 60 mg/kg dose ip, [133], or through multiple low doses of 40
mg/kg iv for five days [134,135]. The single high dose of STZ leads to rapid ablation
of β-cells and therefore produces hyperglycaemia, while the multiple low dose
method induces insulitis in which macrophage-derived proinflammatory cytokines
cause β-cell death [136].
Several studies have been conducted in our laboratory to demonstrate the
cytotoxic effects of STZ in animal models. These studies showed that the deleterious
effect of STZ was mediated by increased ROS production, increased mitochondrial
oxidative stress and upregulation of cytochrome P450 2E1 (CYP 2E1) expression
and glutathione S-transferase activity [137]. Furthermore, our results demonstrated
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that complications associated with oxidative stress were not only observed in the
pancreas but also in the liver, brain and kidney [137,138]. Additionally, offspring of
STZ-induced diabetic rats showed increased oxidative stress and an alteration in how
they metabolised glutathione [139]. We found that STZ increased ROS/RNS
production, oxidative stress and mitochondrial dysfunction in the HepG2 cell line
[140].
Alloxan (2,4,5,6 tetraoxypyrimidine; 5,6-dioxyuracil) is a urea derivative
which causes selective toxicity to pancreatic β-cells and is widely used to induce
type-1 diabetes in experimental animals. The diabetogenic property of alloxan was
first described in 1943 by Dunn and his group [141]. They reported pancreatic
necrosis in rabbits after alloxan administration. The diabetogenic action of alloxan is
preceded by its rapid cellular uptake by pancreatic β-cells [142,143] and formation of
free radicals [144]. Alloxan is also taken up by liver cells, but because liver is more
resistant to ROS than are pancreatic cells, it is not susceptible to damage. This
explains the selective cytotoxic effect of alloxan to pancreatic β-cells [143].
The formation of ROS is preceded by a reduction of alloxan to dialuric acid
and then re-oxidation back to alloxan, creating a redox cycle for the generation of
superoxide radicals. These break to form hydrogen peroxide and thereafter hydroxy
radicals that causes DNA fragmentation [117]. Other mechanisms of the cytotoxic
effect of alloxan include oxidation of cellular compounds containing a sulphurhydrogen (SH) group, such as reduced glutathione (GSH), cysteine and glucokinase
[145]. Lenzen and his group found that inhibition of glucokinase by alloxan, through
interaction with the SH group on the sugar-binding site, may contribute to the
inhibition of glucose-induced insulin secretion [146,147]. Studies have also found

25
that glucose can counteract the inactivation of glucokinase by hindering access by
alloxan to the SH groups of the enzyme [146,147]. Alloxan has a narrow
diabetogenic dose, and a light overdosing can lead to general toxicity and death of
animals as a result of kidney tubular necrotic toxicity [148].
The main advantage of performing studies using chemically-induced diabetes
is the simplicity and low cost of this technique for triggering the disease. Moreover,
it can be applied not only in rodents but also in higher animals. However, the major
disadvantage of this technique is that the chemicals are toxic to other body organs.
1.3.1.2 Genetics-based models of diabetes
 Genetic models of type-1 diabetes
1) BB rats
This group of rats was bred in Ottawa, Canada, in 1974 from Wistar rats that
had spontaneously developed hyperglycaemia [149]. Two main colonies were
established from the original Canadian colony: one from outbred biobreeding
diabetic-prone rats of the original colony in Ottawa (BBDP) and the other from an
inbred biobreeding diabetic-prone colony in Worcester, Massachusetts (BBDP/Wor)
[150]. BB rats develop pancreatic insulitis followed by selective destruction of βcells. Diabetes develops spontaneously at between 50 and 90 days of age with similar
incidence in females and males [151]. These rats are characterised by severe diabetic
phenotype;

hyperglycaemia,

hypoinsulinaemia,

weight

loss

and

ketonuria,

demanding insulin therapy for survival.
2) LEW 1AR1/-iddm rats
The Lewis insulin-dependent diabetes mellitus rat is a spontaneous model of
type-1 diabetes developed from a congenic Lewis rat colony with a defined major
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histocompatibility complex (MHC) haplotype. It was developed in Hanover Medical
School, Germany, by Lenzen and his group [152]. The MHC haplotype plays an
essential role in the development of autoimmune diabetes [153]. The rats develop
diabetes between 60 and 90 days of age with equal frequency between both genders
[154]. The Lewis model is characterised by rapid progression of insulitis as a result
of extensive infiltration with bone (B) and thymus (T) lymphocytes, macrophages
and natural killer (NK) cells, leading to β-cell destruction via apoptosis [152,155].
The apoptosis of pancreatic β-cells in Lewis rats is induced by expression of
proinflammatory cytokines with inducible nitric oxide synthase (iNOS) and
procaspase 3 [155].
3) Non-obese diabetic mouse (NOD)
The NOD model was first developed at Shionogi & Co Ltd, a leading Japanese
pharmaceutical company, by Tochino Y in 1974 [156]. It is one of the models most
commonly used to understand the genetics and pathogenesis of type-1 diabetes. It
shares

many genetic and immunopathologic characteristics with humans [157,158].

One of the most reliable genetic predictors of type-1 diabetes is the MHC found in
both mice and humans, known as the insulin-dependent susceptibility 1 factor (idd1)
in mice and the insulin-dependent diabetes mellitus 1 factor (IDDM1) in humans
[157,159]. Other genetic factors are related to immune-system function and
regulation, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [160].
The development of diabetes in the NOD model is associated with insulitis and
a decrease in β-cell mass. The difference in diabetes pathogenesis between NOD
mice and humans is the severity of the insulitis, which is less pronounced in humans
than in mice [161]. The onset of diabetes occurs between 18 and 30 weeks of age
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[162], and overt diabetes is more frequently observed in female mice than male.
4) Akita mice
This model was developed in Akita, Japan, from a C57BL/6NS1c mouse due to
the presence of a spontaneous mutation in insulin gene 2 [163]. This mutation causes
incorrect processing of proinsulin, leading to aggregation of misfolded insulin
protein [164] which subsequently leads to endoplasmic stress within β-cells. Akita
mice are characterised by hyperglycaemia, hypoinsulinaemia, polyuria and
polydipsia.
 Genetic models of type-2 diabetes
1) Zucker diabetic fatty rat (ZDF)
This type of rat was discovered in 1961 after Merck M-strain and Sherman rats
were crossed. They are characterised by a mutated leptin receptor that induces
hyperphagia, so by the age of four weeks the rats become obese. The homozygous
mutation of the leptin receptor results in the development of type-2 diabetes when
rats are fed with a high-energy rodent diet. ZDF rats develop insulin resistance and
glucose intolerance between three and eight weeks of age and turn apparently
diabetic between eight and 10 weeks of age. We found that the associated
complications with diabetes in ZDF rats is mediated by increased oxidative stress,
mitochondrial dysfunction, altered GSH metabolism and cell signalling [165]. These
complication were found in many tissues, including kidney and pancreas [166], liver
and brain [165], and heart [167].
2) Goto-Kakizaki rats (GK)
The GK rat is a spontaneous model of type-2 diabetes characterised by glucose
intolerance and insufficient glucose-induced insulin secretion. It is considered a non-
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obese model. It was established by a Japanese group by repetitive inbreeding of
Wistar rats which showed impaired glucose intolerance [168]. GK is not an insulinresistant model, but rather the rats have a defect in insulin secretion and glucose
metabolism due to reduce β-cell mass [169] and function [170]. Differences in islet
morphology and function have been reported between different colonies of GK rat.
In colonies developed in Stockholm, Sweden, and Dallas, US, the volume and
density of β-cells is comparable to those in the control, therefore the hyperglycaemia
produced is due to a defect in insulin secretion. However, in the Paris, France, colony
a reduction in β-cell mass has been reported [170]. In our lab we have found that
aspirin treatment improves glucose tolerance and increases the insulin responses in
GK rats, which may be due to the anti-inflammatory action of aspirin and enhanced
nitric oxide (NO) level that facilitates insulin signalling [171]. Also, we have found
that exercise has a great impact in improving the mitochondrial function and
inducing energy metabolism. This is assumed by observations of increases in
hexokinase and glutamate dehydrogenase activities in GK rats, as well as reductions
in the complications associated with oxidative stress [172].
1.3.2 In vitro models of diabetes
The pharmaceutical industry uses in-vitro models of diabetes to screen a tested
drug initially and to find novel therapeutic targets. These models also provide
improved understanding of the cellular and molecular mechanisms of tested drugs. In
vitro models of diabetes are derived from:
1) Primary cell cultures
Cells are isolated directly from normal, diabetic or transgenic animals through
collagenase digestion techniques followed by separation. After isolation, they are
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transferred to an appropriate culture medium. Cells in primary culture have the same
karyotype as those of the original tissue and have a limited life span. The limitation
of primary-cell cultures is that due to early differentiation, these cells are not suitable
for a repeated passage and long-term studies.
2) Insulin-secreting cell lines
Examples of insulin-secreting cell lines include: RIN, HIT, beta-TC, MIN6 and
INS-1 cells. These cell lines are useful tools for studying cell functions at the cellular
and molecular levels. These cellular models are frequently used under in vitro
conditions and after multiple passages which sustain their proliferation and other
metabolic abilities, so they show better responses than primary cultures.
3) Ex-vivo tissue or tissue homogenates derived from animal models
These depend on the isolation of major tissues involved in the pathophysiology
of diabetes, such as tissue from the pancreas, liver, muscle and adipose areas.
Afterwards, the tissue homogenate is analysed.

1.4 Common anti-diabetic drugs/ compounds with anti-oxidant potential
Metformin is a biguanide glucose-lowering agent used for the treatment of
T2DM. It is usually described as a first-line pharmacological treatment. Metformin
has an anti-glycaemic effect because it decreases hepatic glucose through inhibition
of liver gluconeogenesis [173], stimulates glucose uptake by the skeletal muscles
[174] and reduces glucose absorption from the intestine [175]. Recently, it has been
shown that metformin acts as an inhibitor of the mitochondrial complex I activity
[176], decreasing the ATP reduction and eventually leading to the activation of
AMP-activated protein kinase (AMPK) [174]. AMPK is a cellular energy sensor,
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which is activated by a decrease in the ATP/ADP ratio. The increase in AMPK
activity stimulates fatty acid β-oxidation in liver and muscle, increasing glucose
uptake by the muscle and inhibiting hepatic glucose production and lipogenesis
[174,177]. Studies report that metformin exhibits anti-oxidant action by restoring the
redox homeostasis via reductions in expression of NADPH oxidase and increases in
those of the enzymes SOD and GPx [178]. Moreover, it attenuates lipid peroxidation
[179].
Repaglinide belongs to the meglitinides anti-diabetic class of drugs. It
promotes insulin secretion by closing ATP-dependent potassium channels in
pancreatic β-cells [180]. This leads to membrane depolarisation and the opening of
voltage-sensitive calcium channels, which consequently causes a translocation of the
secretory granules to the cell surface and insulin exocytosis. One experimental study
on diabetic rabbits showed that the antioxidant effect of Repaglinide was mediated
by upregulation of GSH-reductase and glutathione levels [181]. Moreover, the same
study found that the level of ascorbic acid was significantly increased in the plasma
of treated rabbits, accompanied by a reduction in protein oxidation. Furthermore,
repaglinide significantly reversed the increases in the levels of malondialdehyde and
decreases in SOD and GSH as observed in the cyclosporin A-induced renal injury rat
model [182] and diabetic model [183].
Glibenclamide is a third generation of sulphonylurea anti-diabetic drugs. It is
an insulin secretagogue with a similar mechanism of action to repaglinide, acting on
ATP-dependent potassium channels by activating sulphonylurea receptors in β-cells
[184]. Similarly to metformin and repaglinide, the antioxidant effect of
glibenclamide is mediated by upregulation of SOD catalase and GSH reductase
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[183]. However, the inhibition of MDA concentration was more pronounced with
metformin and repaglinide than with glibenclamide in alloxan-induced diabetic rats
[183].
Resveratrol is a nonflavonoid polyphenolic compound present in different plant
species. The anti-diabetic action of resveratrol has been extensively studied in animal
models and in humans. As an anti-diabetic agent, resveratrol reduces blood glucose
concentration by increasing glucose uptake/utilisation, inducing glycogenesis in liver
and skeletal muscle [185] and restoring the abnormal insulin-signalling pathways.
Several studies have reported that resveratrol induces p-Akt expression in STZdiabetic rats and increase GLUT4 translocation to the cell membrane in diabetic rats
[186]. The beneficial effect of resveratrol is strongly related to the activation of
AMPK which in turn regulates several processes, for example energy metabolism,
mitochondrial functions and cellular homeostasis [187]. The antioxidant effect of
resveratrol is exerted by activation of Nrf2, which in turn upregulates the antioxidant
proteins, heme oxygenase-1 (HO-1) and GPx [188,189]. Clinical studies have shown
that co-administration of resveratrol with glibenclamide and/or metformin improves
the glycaemic control, [190] blood pressure and total cholesterol, and improves
insulin sensitivity in T2DM [191].
NAC is an acetylated cysteine residue and a precursor of reduced glutathione
(GSH). It is a sulphydryl donor which regenerates GSH, stimulates the activity of
glutathione S-transferase and acts as a scavenger through its direct interaction with
ROS [192]. NAC is a membrane-permeable cysteine precursor that does not require
active transport. Once inside the cell, it is rapidly hydrolysed to release cysteine
residue [193]. The synthesis of GSH is limited by the availability of cysteine [194].
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Clinically, NAC is used as a mucolytic agent in patients with cystic fibrosis [195], as
an antidote in the treatment of acetaminophen overdose [196] and in the prevention
of non-alcoholic steatohepatitis (NASH), characterised by decreased GSH and
increased oxidative stress [197]. NAC is considered a better source of glutathione
than glutathione itself, due to the low oral absorption of the latter. Several studies
have reported the potential protective effects of NAC against diabetes, in reducing
hyperglycaemia and inhibiting ROS production. Experimental studies have reported
that NAC reduced hyperglycaemia and inhibited alloxan-induced NF-kB activation
in mice [198]. Studies have shown also that NAC prevented a decrease in insulin
content and mRNA expression [199,200]. NAC also has a beneficial role in diabetic
complications. Studies have shown that NAC inhibits the development of the
peripheral neuropathy in streptozotocin-induced diabetic rats [201] and protects from
diabetic cardiomyopathy, through inhibiting ROS production and fibrosis [202].

1.5 Aims and objectives
Elevated levels of glucose and fatty acids are the main characteristics of
metabolic disorders such as diabetes and obesity, associated with increased oxidative
stress, mitochondrial dysfunction and inflammation. Once the primary pathogenesis
of diabetes is established, which is potentially linked to both genetic and
environmental factors, hyperglycaemia and hyperlipidaemia exert further destructive
and/or toxic effects on β-cells. The concept of glucolipotoxicity has arisen from the
combination of the deleterious effects of the chronic elevation of glucose and fatty
acid levels on pancreatic β-cells function and/or survival. Studies have shown that
elevated glucose levels augment the effect of FFA-induced cell death, because high
quantities of glucose inhibit fat oxidation, and consequently lipid detoxification.
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Though numerous studies have been carried out in this field, the exact molecular
mechanisms and causative factors need to be established. This is because of the
physiological, physical, endocrine, dietary and environmental factors working in
tandem. Therefore, our focus in the present study is to elucidate the molecular and
cellular mechanisms of pancreatic β-cell toxicity in the presence of high glucose/fatty
acid levels using an in vitro model of insulin-secreting pancreatic cells Rin-5F. Since
STZ, a known pancreatic β-cell toxin, is a structural analogue of glucose, we have
designed a pilot study to investigate the molecular mechanism(s) of cytotoxicity of
STZ using Rin-5Fcells, thus providing a primary insight to the mechanism of
glucose-induced toxicity. Also, the study will identify the primary molecular and
metabolic targets in Rin-5F cells affected in STZ toxicity. On the basis of these
results, and similar studies by other researchers, we have extended our study to
evaluate the toxicity of high glucose/fatty acid concentrations under in vitro
conditions. Furthermore, we aim to investigate the effect of NAC treatment on
modulation of cell signalling responses and oxidative stress.
Objectives
 To identify the specific molecular and metabolic targets affected under high
glucose (25 mM)/high palmitic acid (up to 0.3 mM) concentrations alone or
in combination and compare these effects with normal glucose-treated Rin-5F
cells.
 To elucidate the protective mechanism(s) of N-acetylcysteine (NAC), an
antioxidant, on glucolipotoxicity in Rin-5F cells.
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1.6 Hypothesis
As discussed above, the glucolipotoxicity induces oxidative stress and
inflammatory

responses

causing

metabolic

adaptation

and

alterations

in

mitochondrial function in many pathologies, including diabetes, obesity, cancer and
cardiovascular diseases. However, under in vivo conditions, these alterations may be
cumulative effects of multiorgan-specific physiological responses running in tandem.
It is not clear, however, how individual cell systems will respond when exposed to
high glucose and high fatty acid levels under in vitro conditions. In the present study,
therefore, we plan to investigate glucolipotoxicity directly using pancreatic insulinsecreting Rin-5F cells in a cell-culture system. Our hypotheses are to elucidate
whether:
1) Glucolipotoxicity induces inflammatory responses and oxidative stress in an
isolated cell system under in vitro conditions.
2) Glucolipotoxicity

induces

metabolic

alterations

and

mitochondrial

dysfunction leading to energy metabolism adaptations.
3) Glucolipotoxicity alters molecular signalling for cell survival and apoptosis
(cell death).
4) High glucose concentrations, alone or in combination with increasing
concentrations of saturated fatty acid (e.g. palmitic acid), have potentiation
effects on glucolipotoxicity.

1.7 Significance of the study
The potential significance of the present study is to elucidate the direct effects
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of the elevated levels of glucose and/or fatty acids on cellular functions, without the
involvement of other factors such as physiological, physical, endocrine, dietary and
environmental effects seen in an in vivo animal model. This would help in better
understanding the aetiology and pathophysiology of diabetes and obesity and to
manage the hyperglycaemia and hyperlipidaemia observed in disease conditions
using pharmaceutical interventions.
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Chapter 2: Materials and Methods

2.1 Materials
STZ, reduced and oxidised glutathione (GSH/GSSG), 1-chloro 2, 4dinitrobenzene (CDNB), cumene hydroperoxide, glutathione reductase, 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), NADH, NADPH,
cytochrome c, coenzyme Q2, antimycin A, dodecyl maltoside, 7-ethoxyresorufin,
methoxyresorufin, Hoechst 33342, fatty acid-free BSA, palmitic acid and kits for
ATP and HK were purchased from Sigma (St Louis, MO, USA), while 2',7'Dichlorofluorescein diacetate (DCFDA) was procured from Molecular Probes
(Eugene, OR, USA). Kits for nitric oxide and caspase-3, -8 and -9 assays were
purchased from R & D Systems (MN, USA) and that for lipid peroxidation (LPO)
and aconitase from Oxis Int, Inc. (Portland, OR, USA). Kits for GSH/GSSG assays
were procured from Promega Corp. (Madison, WI, USA). Apoptosis detection kits
for flow cytometry and TNF-α kits were purchased from BD Pharmingen (BD
Biosciences, San Jose, USA). Kits for catalase were purchased from Cayman (MI,
USA). Kits for SOD were purchased from Trevigen (Gaithersburg, MD, USA).
Those for GDH and PGE2 were purchased from Abacam (Cambridge, UK). Kits for
insulin were purchased from Cisbio (Codolet, France). Multi-analyte ELISA array
kits were purchased from Qiagen (Düsseldorf, Germany). Rin-5F cells were obtained
from the American Type Culture Collection (Manassas, VA, USA). Polyclonal
antibodies against caspase-3 and -9, PARP, iNOS, Nrf2, Bcl-2, Bax, GLUT 2, NFκB, cyt c and β-actin were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA), while those against Atg5, LC3 II, AMPK, p-AMPK, mTOR, pmTOR, Akt and p-Akt were purchased from cell signalling (Danvers, MA, USA).
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Reagents for cell culture, SDS-PAGE and Western blot analyses were purchased
from Gibco BRL (Grand Island, NY, USA) and Bio Rad Laboratories (Richmond,
CA, USA).

2.2 Methods
2.2.1 Cell line
Rin-5F is a secondary clone of the rat islet tumour cell line, RIN-m. The cells
produce and secrete insulin, produce L-dopa-decarboxylase and contain membranebound secretory granules. Unlike the parental cell line, they do not produce
somatostatin. Rin-5F cells have been used as a model in the study of pancreatic islet
cells, in particular, the mechanisms controlling insulin synthesis, storage and
secretion.
2.2.2 Cell culture and treatment
Rin-5F cells were grown in poly-L-lysine coated 75 cm2 flasks (~2.0–2.5 ×106
cells/ml) in RPMI-1640 medium supplemented with 1% non-essential amino acids, 2
mM glutamine, 10% heat-inactivated foetal bovine serum (FBS), in a humidified
incubator in the presence of 5% CO2–95% air at 37°C. For STZ treatment, cells were
treated with different concentrations of STZ (0–10 mM) dissolved in citrate buffer,
pH4.4 and diluted in RPMI 1640 to appropriate concentrations just prior to use at
different time intervals (24 h-48 h). Control cells were treated with the vehicle alone.
For NAC treatment, cells were treated with 10 mM NAC two hours prior to STZ
treatment. Concentrations and time points for STZ treatment in this study were based
on MTT cytotoxicity tests and previous published reports [140,203].
For fatty acid treatment, palmitic acid was dissolved in ethanol and heated to
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40°C for 10 min to make a stock solution of 100mM and then conjugated to 1% fatty
acid free-BSA in a molar ratio of 6:1. The palmitate/BSA conjugate was added to the
cultured cells in RPMI supplemented with 1% FBS to generate a final concentration
of 0.06 mM and 0.3 mM palmitate. Concentrations and time points were based on
MTT cytotoxicity tests and previous published reports [204,205]. Moreover, in
physiological conditions, palmitic acid concentrations in the plasma range from 0.3
to 4 mmol/L [206]. For high glucose treatment, cells were grown in normal glucose
(11 mM) media to confluent, then cells were treated with high glucose (25 mM)
alone or in combination with palmitic acid. Under physiological conditions, glucose
concentrations range between 5.5–6 mmol/L with a maximum of ∼9 mmol/L
postprandially [207,208] . Control cells for normal and high glucose media were
treated with vehicle (BSA/ethanol- max ethanol <0.01%) alone. For NAC treatment,
cells were treated with 10 mM NAC 2 h prior to the palmitic acid treatment. After
the desired time of treatment, cells were harvested, washed with phosphate-buffered
saline (PBS, pH7.4) and homogenised in H-medium buffer (70 mM sucrose, 220 mM
mannitol, 2.5 mM HEPES, 2 mM EDTA, 0.1 mM phenylmethylsulphonylfluoride,
pH 7.4) at 4°C. Mitochondrial and post-mitochondrial fractions were then isolated by
differential centrifugation. Protein concentration was determined by performing a
Bradford assay [209].
2.2.3 MTT cell viability assay
Mitochondrial dehydrogenase activities were determined by MTT assay. Cells
were seeded in 96 well plates on confluence. They were treated with STZ or high
glucose/high palmitic acid for the desired time interval. The cell viability was
assessed by the reduction of MTT dye to form insoluble purple formazan crystals.
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The crystals were dissolved in acidified alcohol, and the viable cells were quantified
using an ELISA reader (TECAN Infinite M 200 PRO, Austria) at 550 nm after
subtracting the appropriate control value.
2.2.4 Measurement of reactive oxygen species (ROS)
Intracellular production of peroxides was measured fluorimetrically using the
DCFDA-dependent fluorescence method. DCFDA is not fluorescent by itself. It is
converted by intracellular esterases to 2, 7-dichlorodihydrofluoresc, which is
subsequently oxidised by hydrogen peroxide to the highly fluorescent, 2,7dichlorodihydrofluorescein (DCF). Briefly, cells were seeded in 96 well plates and
allowed to grow and form a confluent layer and then were treated with STZ or high
glucose/high palmitic acid for the desired time. Cells were then incubated with 5µM
DCFDA for 30 min at 37°C. Unreacted DCFDA was then washed off with PBS and
plates read on the ELISA reader (TECAN Infinite M 200 PRO, Austria) at an
excitation wavelength of 488 nm and an emission wavelength of 525 nm.
Measurement of ROS production was also assessed by flow cytometry. For
this, Rin-5F cells were treated with STZ or high glucose/high palmitic acid for the
required time intervals, trypsinised and counted. A fraction (1×105 cells/100 µl) of
the cell suspension was incubated with 5 μM DCFDA for 30 min at 37°C in the dark.
Cells were then washed and resuspended in PBS, fluorescence was analysed by flow
cytometry using FACSCanto software as described before [210].
2.2.5 Measurement of NO production
Nitric oxide (NO) is a highly reactive molecule, playing a vital role in vascular
homeostasis, neurotransmission and host defence mechanisms [211]. The NO
formation is catalysed by NO synthase (NOS) through a series of redox reactions,
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with degradation of L-arginine to L-citrulline and NO, in the presence of oxygen and
NADPH [212]. The biochemistry of NO metabolism depends on the stepwise
oxidation to nitrite and nitrate [213]. NO is a diatomic gaseous free radical that has
an extremely short half-life of less than one second in circulating blood [214]. Due to
its instability it is very difficult to measure directly, therefore the accurate detection
of NO depends on the quantification of NO metabolites in the sample (nitrite and
nitrate).
The principle of NO assayed by NO kit (R&D Systems, Inc.) is based on the
enzymatic conversion of nitrate to nitrite by nitrate reductase, followed by the
colorimetric detection of nitrite as an azo dye product of the Griess reaction. The
Griess reaction is based on the two-step diazotisation reaction in which acidified NO2
produces a nitrosating agent, which reacts with sulphanilic acid to produce the
diazonium ion. This ion is then coupled to N-(1-naphthyl) ethylenediamine to form
the chromophoric azo-derivative which absorbs light at 540-570 nm.
2.2.6 Measurement of lipid peroxidation
Lipid peroxidation (LPO) is the oxidative degradation of lipids by reactive
oxygen species. This process involves the action of ROS on the polyunsaturated fatty
acids of the cell membrane, in which the free radicals conjugate with electrons in the
lipid bilayer of the cell membrane, initiating a self-propagating chain reaction that
results in cell damage. The destruction of membrane lipids and the end-products of
lipid peroxidation are particularly toxic to cells and even tissues [215].
Measurements of the end products, malondialdehyde (MDA) and 4hydroxyalkenals, have been used as indicators and biomarkers of lipid peroxidation
and oxidative stress. In our study, the LPO assay was measured using the LPO-586TM

41
kit, according to the manufacturer’s recommended protocol, and the concentration of
MDA was calculated from the standard curve. The colorimetric assay is based on the
reaction of the chromogenic reagent (N-methyl-2-phenylindole) with MDA in the
presence of hydrochloric acid (HCl) at 45°C. One molecule of MDA reacts with two
molecules of the reagent to produce a stable chromophore with maximal absorbance
at 586 nm. Briefly, standards and samples were mixed with the reagent followed by
the addition of 37% HCl incubated at 45°C for 60mins, centrifuged and the clear
supernatant read at 586 nm.
2.2.7 Measurement of NADPH oxidase activity (NOX)
NADPH oxidase (NOX) activity was measured using the lucigenin‐enhanced
chemiluminescence method as described before [165,172]. The concept of NADPH
as a source of ROS had developed from inhibitor studies. It was first observed that
the formation of ROS is potentially sensitive with NOX inhibitors diphenylene
iodonium (DPI) and apocynin [216]. In the present experiment we used apocynin,
which is a reversible inhibitor of NADPH oxidase activity, that inhibits the assembly
of the p47phox subunit with the membrane complex [217]. Both plasma membranebound apocynin-sensitive NOX dependent as well as mitochondrial-dependent ROS
production were measured. Briefly, cell extracts were reacted with lucigenin in the
presence of 0.1M potassium phosphate buffer at pH 7.4. The reaction was initiated
by the addition of NADPH and the chemiluminescence measured using the Turner
Designs TD‐20/20 luminometer. NOX activity was expressed as relative
chemiluminescence (light) units (RLU)/min/mg protein.
2.2.8 Measurements of catalase activity
Catalase enzyme, which catalyses the decomposition of hydrogen peroxide to
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molecular oxygen and water, was assayed using the catalase kit (from Cayman MI,
USA). Measurement of catalase was based on its peroxidatic activity, which
depended on its ability to catalyse the oxidation of alcohol such as methanol by
hydrogen peroxide. The formaldehyde produced was measured colorimetrically in
the presence of a chromogen, purpald, which upon oxidation, changed from
colourless to purple. The absorbance was read at 450 nm (Figure 8, modified from
[218]).

Figure 8: Catalase metabolism.

2.2.9 Measurement of superoxide dismutase activity (SOD)
The principle of the superoxide dismutase assay was based on the conversion
of xanthine to uric acid and hydrogen peroxide by xanthine oxidase. The superoxide
ions produced reduced the nitroblue tetrazolium (NBT, yellow, water soluble) to
NBT-diformazan (dark-blue, water insoluble). Since SOD catalyses the dismutation
of two superoxide radicals to hydrogen peroxide and oxygen, the SOD activity was
measured as the percentage of inhibition of NBT-diformazan formation, according to
the vendor's protocol (R&D System, MN, USA). Briefly, cell lysates were mixed
with 60 µl of diluted reaction buffer, 7.5 µl of xanthine solution and 30 µl of NBT
solution, and zero-time absorbance was measured at 550 nm. Xanthine oxidase
solution (10 µl) was then added and absorbance measured at five-minute intervals.
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2.2.10 Nuclear staining with Hoechst 33342
Hoechst 33342 is a blue fluorescent DNA dye that stains the condensed
chromatin in apoptotic cells [219,220]. Cells were grown on cover slips and treated
with STZ or high glucose/high palmitic acid concentrations for the required time.
After treatment, cells were fixed with 3.7% formaldehyde, stained with Hoechst
33342 (10 µg/ml) and incubated for 20 min at room temperature. The cover slips
were washed twice with PBS, mounted on glass slides and analysed by fluorescence
microscopy.
2.2.11 Measurement of apoptosis by flow cytometry
FACS analysis was performed to measure the apoptotic changes in the plasma
membrane by concurrent staining with Annexin V and propidium iodide (PI).
Briefly, according to the protocol of the vendor, BD Biosciences (San Jose, CA,
USA), treated cells were trypsinised and centrifuged at 1000 rpm for 10 minutes. The
supernatant was discarded, and cells were washed twice with PBS and re-suspended
(1×106 cells/ml) in binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM
CaCl2). A fraction (100 µl/1×105cells) of the cell suspension was then incubated with
5 µl Annexin V conjugated to FITC and 5 µl PI for 15 mins at 25°C in the dark.
Binding buffer (400 µl) was added to the suspension and apoptosis measured
immediately using a Becton Dickinson FACScan analyser, as described before
[221,222]. Use of this method enabled the distinguishing of viable cells (AV−/PI−)
and cells undergoing necrosis (AV+/PI+). The apoptotic cells were assessed by the
percentage of positively stained cells with annexin V while still excluding PI
(AV+/PI−). The results are represented as dot plots with quadrant gates showing
early apoptosis in quadrant 4 and late apoptosis in quadrant 2.
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2.2.12 DNA fragmentation assay
Agarose gel electrophoresis is an efficient and effective way of separating
DNA fragments of varying sizes ranging from 100 bp to 25 kb [223]. Briefly, treated
and untreated control cells were harvested and centrifuged at 1000 rpm for 10 min at
4°C and the cells washed twice with PBS. The pellet was re-suspended in lysis buffer
(50 mM Tris, pH 7.5, 3% IGEPAC, 20 mM EDTA), for 5 mins and then centrifuged
at 1000 rpm for 5 mins at 4°C. The resulting supernatant was transferred into new
Eppendorf tubes and incubated with 10% SDS and 10 mg/ml RNase A, for 2 h at
56°C, and then further incubated for 2 h with 10mg/ml protein kinase K.
Subsequently, the DNA was precipitated with an equal volume of 3M sodium acetate
and 2.5volume of ice-cold absolute ethanol at -20°C. The tubes were then
centrifuged at 13,500 rpm for 20 min. The supernatant was discarded, and the pellets
air-dried and re-suspended in TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM
EDTA) and incubated for 5 mins at 56°C. Electrophoresis of the DNA samples was
performed on a 1.8% agarose gel containing 0.5 μg/ml ethidium bromide at 40V for
2-3 h. The electrophoretically separated DNA fragments stained with ethidium
bromide were visualised using the Typhoon FLA 9500 system (GE Healthcare,
Uppsala, Sweden), as described before [210,224].
2.2.13 Caspase activity
Apoptosis was also assessed by measuring the activities of the caspases -8, -9
and -3 in the cell lysates. The assays were based on the conjugation of caspasespecific peptide substrate with the chromophore p-nitroanilide (pNA), IETD-pNA,
LEHD-pNA and DEVD-pNA for caspase -8, -9 and -3 respectively. When the
peptide was cleaved by the respective caspases, the chromophore was released and
light emission measured at 405 nm using the plate reader, as described in the
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manufacturer’s protocol (R&D Systems). Briefly, cells were grown in 96 well plates
and treated with STZ or high glucose/high palmitic acid concentrations as mentioned
earlier in the Materials and Methods. After the required time for treatment, the
medium was replaced by lysis buffer and incubated for 10 mins; 50 µl of the cell
lysates were then treated with the respective colorimetric substrate and incubated for
1 h at 37°C. The absorbance was measured at 405 nm.
2.2.14 Measurement of activity of cytochrome 450 (1A1 and 1A2) enzymes
Cytochrome P450 (CYP) is a hemeprotein that plays central roles in drug and
xenobiotic metabolism as well as in steroid hormone synthesis, fat-soluble vitamin
metabolism, and the conversion of polyunsaturated fatty acids to biologically active
molecules [225]. Drug metabolism is achieved through phase I reactions, or phase II,
or both. The most common phase I reaction is oxidation, which is catalysed by the
CYP system. It has been established that, during the oxidation process, the
cytochrome P450 system produces reactive oxygen species such as superoxide
radicals and hydrogen peroxide [226]. Moreover, the heme moiety of the cytochrome
P450 system can serve as an intracellular source of iron capable of catalysing free
radical reactions [227]. The CYP1A1-dependent EROD activity and CYP1A2dependent MROD activity were measured spectrofluorometrically using 7ethoxyresorufin and methoxyresorufin respectively as substrates [228,229] by
standard methods as described before [166,230,231]. Briefly, the reaction mixture
composed of assay buffer (0.1 mM Kpi, pH 7.4 and 0.1 mM MgCl2, 80 mg NADPH,
80 mg BSA) and substrate (ethoxyresorufin for CYP 1A1 or methoxyresorufin for
CYP 1A2), and the cell extracts were incubated at 37○C for 30 mins. Methanol was
added to stop the reaction and tubes centrifuged for 10 min at 1000 rpm. The
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supernatants were removed and the activities of CYP 1A1/1A2 were measured at
Ex/Em 528/590 and calculated using a standard curve plot using different
concentrations of resorufin run under the same conditions.
2.2.15 Measurements of GSH/GSSG ratio
GSH/GGSG ratios were measured using the GSH/GGSG-Glo kit as per the
vendor’s protocol. Briefly, cells were grown in 96 well plates and treated as
mentioned in the Materials and Methods. The treated cells were then lysed with
either total or oxidised glutathione lysis reagents. For the oxidised glutathione
measurement, the reduced GSH was blocked using NEM reagent and the oxidised
glutathione was reduced. The total reduced glutathione, in turn, converted LuciferinNT to luciferin in the presence of GST enzyme coupled to firefly luciferase. The
luciferin so formed gave a luminescent signal, which was proportional to the amount
of GSH present. The total and oxidised glutathione were then measured from the
standard curve and the GSH/GSSG ratios calculated.
2.2.16 Measurements of glutathione-S-transferase activity (GST)
The activity of GST, using 1 chloro-2, 4-dinitrobenzene (CDNB) as substrate,
was measured as described by Habig et al. [232] with slight modifications. Briefly,
cell extracts were added to a reaction mixture, composed of 0.3 M Kpi buffer, pH
6.5, 3 mM GSH, and 0.15 M CDNB. The reaction was carried out at 25°C, and the
change in absorbance at 340 nm was monitored for 3 mins using a
spectrophotometer. All initial rates were corrected for the background non-enzymatic
reaction. One unit of activity is taken as the formation of 1 µmol of product per
minute at 25°C (extinction coefficient at 340 nm = 9.6 mM-1 cm-1 for CDNB).
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2.2.17 Measurement of GSH reductase
The activity of GSH reductase, using oxidised glutathione (GSSG) as substrate,
was measured by standard protocol by Smith et al. [233]. Briefly, the extracted cells
were added to a reaction mixture composed of 0.1 M Kpi, pH 7.4, 1 mM EDTA,
2mM NADPH and a substrate of GSSG (20 mM). The reaction was carried out at
25°C, and the decrease in absorbance at 340 nm was monitored for 3 mins using a
spectrophotometer. (extinction coefficient 6.22 mM-1 cm-1).
2.2.18 Measurement of GSH peroxidase (GSH-Px)
GSH-Px activity was measured indirectly by a coupled reaction with
glutathione reductase using cumene hydroperoxide as substrate. Oxidised glutathione
(GSSG), produced by reduction of cumene hydroperoxide by GSH-Px, is recycled to
its reduced state by glutathione reductase and NADPH (Figure 9). The activity of
GSH-Px, measured by the oxidation of NADPH to NADP+, is accompanied by a
decrease in absorbance at 340 nm (ε = 6.22 mM-1 cm-1). The rate of decrease in
absorbance is directly proportional to the activity of GSH-Px. Briefly, the reaction
mixture, composed of 50 mM KH2PO4/5 mM EDTA buffer, pH 7.0, 28 mM
NADPH, 1.125 M NaN3, 0.5 mM GSH and 10 units of glutathione reductase, was
incubated for 10 mins at 25°C before adding the cell extract. The reaction was
initiated by the addition of 6 M cumene hydroperoxide, and absorbance measured
using the spectrophotometer at 340 nm for 2 mins. Results are expressed as
nmol/min/mg protein.
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Figure 9: Measurement of glutathione peroxidase.

2.2.19 Measurement of activity of mitochondrial complexes
Mitochondria were isolated by differential centrifugation, a technique based on
the separation of organelles according to their size and sedimentation velocity.
Briefly, harvested cells were washed twice with cold PBS and homogenised in Hmedium buffer (70 mM sucrose, 220 mM mannitol, 2.5 mM HEPES, 2 mM EDTA,
0.1 mM phenylmethylsulphonylfluoride, pH 7.4) using the Dounce homogeniser.
The homogenates were first centrifuged at low speed to separate out the cell debris
and nuclei, then centrifuged at high speed to isolate the mitochondria. Isolated
mitochondria were suspended in 20 mM KPi buffer, pH 7.4, in the presence of the
detergent, lauryl maltoside (0.2%). The activities of NADH ubiquinone
oxidoreductase

(Complex

I),

succinate-ubiquinone

oxidoreductase/ubiquinol-

cytochrome c oxidoreductase (Complex II/III) and cytochrome c oxidase (Complex
IV) were measured using the substrates coenzyme Q2, succinate and reduced
cytochrome c, respectively, using the methods of Birch-Machin and Turnbull [234]
as described before [165,235] .
Complex І specific activity was measured by following the decrease in
absorption due to the oxidation of NADH at 340 nm (ε = 6.81 mM-1cm-1). Briefly,
1% NADH, 10% BSA, 2% dodecyl maltoside, 0.1 M sodium azide and 1mg/ml of
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antimycin were added to the assay buffer composed of 50 mM Kpi, pH 7.2 and 5
mM MgCl2. Mitochondria (10-20µg) was added and the NADH: ubiquinone
oxidoreductase activity measured for 1 min. This was followed by the addition of
coenzyme Q2 and the activity was measured for an additional 1 min. Rotenone (2
µg/ml) was added to check the inhibition of complex I activity. The activity was
expressed as nmol/mg protein.
Complex II/III activity was measured by monitoring the reduction of
cytochrome c at 550 nm. Briefly, the substrate (1M succinate) was added to the
reaction buffer (50 mM KPi buffer, pH 7.2, 5 mM MgCl2) and 2.5 mM oxidised
cytochrome c. Rotenone (2 µg/ml) and 0.1M sodium azide were added to block the
activities of Complex I and Complex IV respectively. Mitochondrial protein (10-20
µg) was added and the activity of Complexes II/III was measured for 2 mins at 550
nm (ε = 19.1 mM-1cm-1). The activity was expressed as nmol/mg protein.
Complex IV activity was measured by following the decrease in absorption due
to the oxidation of reduced cytochrome c at 550 nm (ε = 19.1 mM-1cm-1). The assay
was performed using 0.1 µg of mitochondrial protein and using 50 µM of reduced
cytochrome c which acted as an electron donor. The assay mixture was composed of
1 M Tris-HCl pH 7.0, 0.44 g of KCl and 4.27 g of sucrose in a final volume of 1 ml.
The activity of Complex IV was measured for 1 min and the initial rate of
cytochrome c reduction was used to calculate the activity. Complex IV activity was
expressed as nmol/mg protein.
2.2.20 Measurement of ATP content
The bioluminescence of ATP was used to measure the ATP content in treated
Rin-5F cells using the luciferin-luciferase reaction following the manufacturer’s
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recommendation (Sigma, St Louis, MO). ATP is the limiting and the key factor in
the bioluminescence reaction [236]. Luciferase is a sensitive biological sensor used
for measuring ATP. The reaction is based on the oxidation of luciferin by luciferase
and the subsequent light emission, which is directly proportional to the amount of
ATP present. ATP powers the luciferase-mediated conversion of luciferin into
adenyl-luciferin. The adenyl-luciferin is subsequently oxidised to form oxyluciferin,
which rapidly produces a chemiluminescent signal in the form of photon emission.
The signals were read using the TD-20/20 Luminometer (Turner Designs,
Sunnyvale, CA) (Figure 10).
Briefly, cells were grown in 96 well plates and then treated as mentioned
earlier. After the desired treatments, cells were lysed with somatic cell releasing
reagent. This leads to the release of cellular ATP by altering the membrane
permeability. An appropriate amount of the lysate was then mixed with the luciferinluciferase mix and the light released was immediately measured using a Turner
Designs 20/20 luminometer. The emitted light was proportional to the ATP
concentration in the sample.

Figure 10: ATP bioluminescence.

2.2.21 Measurement of mitochondrial aconitase activity
The ROS-sensitive mitochondrial aconitase activity was assayed using the
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Bioxytech Aconitase-340 kit. The assay was based on the measurement of the
concomitant formation of NADPH from NADP+ during the isomerisation of citrate
to isocitrate, which is converted to α-ketoglutarate in the presence of isocitrate
dehydrogenase (Figure 11). The rate of NADPH production at 340 nm is directly
proportional to the activity of aconitase enzyme. Briefly, equal volumes of cell
extracts and substrate, enzyme and NADP provided by the kit were incubated for 15
mins at 37○C. Then, the increase in absorbance was measured for 5 mins at 340 nm.

Figure 11: Measurement of aconitase enzyme.

2.2.22 Measurement of mitochondrial membrane potential MMP (Δψm)
The mitochondrial membrane potential (Δψm) was measured by flow
cytometry using a fluorescent cationic dye, DePsipher, according to the vendor’s
protocol (DePsipherTM, R &D System Inc.) as described before [221]. DePsipher can
enter the cells, aggregate and form orange-red fluorescence (absorption/emission
585/590 nm), in its multimeric form, when the membrane potential/polarisation is
maintained. If the membrane potential is reduced, the dye cannot access the
transmembrane space and remains in its green fluorescent (510/527 nm) monomeric
form. Briefly, treated and untreated cells were harvested, resuspended (1×106
cells/ml) in 1ml of diluted DePsipher dye (5 µg/ml) and incubated for 20 mins at
37°C in the dark. The cells were then washed twice and resuspended in PBS. The
MMP was measured immediately using a Becton Dickinson FACSCanto analyser.
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2.2.23 Measurements of insulin levels
Insulin levels were measured using the insulin assay kit which employs
Fluorescence Resonance Energy Transfer (FRET) (Cisbio, Codolet, France). A
FRET assay involves two different anti-insulin antibodies, one labelled with
europium cryptate, and the other with XL665. The FRET phenomenon occurs when
insulin molecules and the two antibodies come into close enough proximity to form a
sandwich. The energy measured is proportional to the concentration of insulin in the
samples. Briefly, supernatants from treated and untreated cells were mixed with the
anti-insulin antibodies, incubated for 2 h and the insulin concentration measured
using a spectrofluorometer at (Ex/Em 337/620). The increase in absorbance was
proportional to the concentration of insulin in the sample.
2.2.24 Measurement of glutamate dehydrogenase enzyme activity (GDH)
Glutamate dehydrogenase (GDH) activity was measured using the GDH kit
(Abcam, Cambridge, UK) as per the vendor’s protocol. It is a coupled enzyme assay,
in which GDH in the mitochondria samples reacts with glutamate as a specific
substrate, resulting in the generation of NADH, which, in turn, reacts with a probe,
generating a colorimetric product proportional to the GDH activity. Briefly,
mitochondrial extracts and standards were incubated with the kit’s assay buffer,
GDH developer and glutamate for 30 mins at 37oC and the absorbance measured at
450 nm at five-minute intervals. One unit of GDH was represented as the amount of
enzyme that would generate 1.0 μmole of NADH per minute at pH 7.6 at 37°C.
2.2.25 Measurement of activity of hexokinase (HK)
Hexokinase activity was measured using the HK assay kit (Sigma-Aldrich,
MO, USA) as per the manufacturer’s instructions. Briefly, it was a coupled enzyme
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assay in which glucose was converted to glucose-6-phosphate by HK, which in turn
was oxidised by glucose-6-phosphate dehydrogenase to form NADH. The resulting
NADH reduced a colourless probe to a coloured product which was read at 450 nm.
The amount of NADH produced was determined from the standard curve. One unit
of HK enzyme is taken as the amount that will produce 1.0 µmole of NADH per
minute at pH 8.0 at 37°C.
2.2.26 Measurement of glucose-6-phosphate dehydrogenase enzyme (G6PDH)
G6PDH activity was measured by following the increase in absorption due to
the reduction of NADP to NADPH (Figure 12). Briefly, cell extracts were added to
assay buffer composed of 0.1 M glucose-6-phosphate (substrate), 55mM Tris-HCl,
pH 7.8, with 33mM MgCl2 and 6 mM NADP, and incubated for 7 mins at 30°C, and
the absorbance recorded at 340 nm for 5 mins (ε = 6.22 mM-1 cm-1). The activity was
expressed as units/mg protein.

Figure 12: Glucose-6-phosphate dehydrogenase reaction.

2.2.27 Measurements of cytokines (TNF-α, IL6 and PGE2)
TNF-α, IL-6 and PGE2 were measured in cell supernatant using ELISA kits.
These were obtained from BD Pharmingen (BD Biosciences, San Jose, USA) for
TNF-α and IL-6 assay, and from Abcam (Cambridge, UK) for the PGE2 assay. The
assays were sandwich ELISAs. Standards and samples were added to 96 pre-coated
well plates, with monoclonal antibody against specific cytokines. The wells were
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washed, and the biotinylated antibodies were added followed by addition of
horseradish peroxidase-conjugated streptavidin. The TMB developing solution was
added. This develops colour in direct proportion to the concentrations of cytokines
present in the sample. The TNF-α and IL-6 were measured at 450 nm while PGE2
was measured at 405 nm using the plate reader (TECAN Infinite M 200 PRO,
Austria). The concentrations of the cytokines were calculated from the standard
curve.
2.2.28 Measurements of protein expression (SDS-PAGE Western blot analysis)
Proteins from cell extracts (30 µg) were resolved by 12% SDS-PAGE and
electrophoretically transferred on to nitrocellulose membranes by Western Blotting
[237]. Membranes were blocked for 2 h with 5% (w/v) non-fat milk in TBS-0.05%
Tween-20, to avoid non-specific binding. Transferred proteins were probed with
specific primary antibodies overnight at 4°C, following which the membranes were
washed with TBS-0.05% Tween-20 and TBS, and treated with the appropriate
peroxidase-conjugated (HRP) secondary antibody, diluted in TBS-0.05% Tween-20.
The blots were then developed using an ECL Plus Western Blotting Luminol
Reagent kit and the bands visualised using the Typhoon FLA 9500 system (GE
Healthcare, Uppsala, Sweden). Densitometric analysis was performed using Image J
and expressed as relative ratios normalised against actin or other proteins as
appropriate.
2.2.29 Statistical analysis
Values shown are expressed as mean ± S.E.M. of three individual experiments.
Statistical significance of data was assessed using SPSS software (version 23) by the
ANOVA one-way test and analysis of variance was followed by Dunnett’s post-hoc
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analysis for STZ study and by LSD post-hoc analysis for high glucose/ high palmitic
acid study. P values ≤ 0.05 were considered statistically significant.
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Chapter 3: Results

3.1 The cytotoxicity mechanisms of STZ treatment in Rin-5F cells
3.1.1 Effect of STZ on Rin-5F cell morphology and viability
A decrease in mitochondrial dehydrogenase-based cell survival was observed
only with higher concentrations of STZ after 2-12 h (Figure 13A). Significant
alterations in cell viability were observed even at low concentration after 24-48 h
treatments. The maximum inhibition (60-70%) was observed in cells treated with 10
mM STZ for 24 h and 48 h. Since significant alterations in cell viability were
observed at 24 h and 48 h, with minimal toxicity using 1 mM STZ and maximal
toxicity using 10 mM STZ, these two time points and concentrations were used in
further studies to elucidate the mechanism of STZ toxicity.
Figure 13B shows the morphology of untreated Rin-5F cells (the control) and
that of cells treated with different concentration of STZ at different time intervals.
The figure shows that, after STZ treatment, the normal flattened cells tended to round
off, losing their normal morphology. When the cells were treated with 10 mM STZ
for 48 h, the rounded cells started detaching from the plate, indicating increased cell
death. Phase contrast microscope has been used to visualize the morphology of the
Rin-5F cells after STZ treatment.
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Figure 13: MTT cell viability assay and morphology of cells after STZ treatment.
Rin-5F cells (~2  104) were grown in 96 well plates for 24h and treated with
different concentrations (0–10 mM) of STZ for different time intervals. The
formazan crystals that formed, following the reduction of MTT by metabolically
active (viable) cells, were solubilised in acidified isopropanol and quantitated using
the ELISA reader at 550 nm (A). Results are expressed as mean +/- SEM for three
experiments. Asterisks indicate significant differences (*p≤0.05, **p ≤0.01) relative
to the untreated control cells. The morphological integrity of the STZ-treated and
untreated control cells was also checked and photographed (20X) under a light
microscope (B).
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3.1.2 Effect of STZ on oxidative stress
Increased ROS production in Rin-5F cells treated with different concentrations
of STZ at different time intervals was captured microscopically using the probe
DCFDA, which measured the overall ROS production. Maximum fluorescence was
observed with 10 mM STZ at 24 h and 48 h (Figure 14A). A time- and
concentration-dependent increase in intracellular ROS production was also measured
fluorometrically as shown in Figure 14B. Significant increases in ROS production
were observed, with a marked increase (2-fold and 3-fold) observed with 10 mM
STZ at 24 h and 4 8h, respectively.
Nitric oxide (NO) production was significantly increased (25-40%) in Rin-5F
cells treated with 10 mM STZ for 24 h or 48 h (Figure 15A), whereas a marginal
increase was observed with 1 mM STZ treatment after 48h.
In parallel with ROS production, LPO was significantly increased in a
concentration- and time-dependent manner after treatment with STZ (Figure 15B).
Treatment with 10 mM STZ for 48 h markedly increased the production of
malondialdehyde (MDA). These results clearly indicate the increased oxidative stress
in Rin-5F cells treated with STZ.
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Figure 14: ROS production in STZ-induced cells.
Intracellular production of reactive oxygen species was measured in untreated
(control) and STZ-treated Rin-5F cells with different concentrations (0–10 mM) for
different time intervals, using the cell permeable probe, DCFDA. Cells (~1 ×105
cells/well) were grown on cover slips and incubated with 5 µM DCFDA for 30 min
at 37°C. Cells were washed twice with PBS, and fluorescence was immediately seen
using an Olympus fluorescence microscope. Representative slides from untreated
control and STZ-treated cells from three experiments are shown (2A). The original
magnification was X200. Production of reactive oxygen species was also measured
fluorimetrically in control untreated and STZ-treated cells (2B). Results are
expressed as mean +/- SEM of three experiments. Asterisks indicate significant
differences (*p≤0.05, **p ≤0.01) relative to the untreated control cells.
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Figure 15: NO production and lipid peroxidation in STZ-induced cells.
NO production was determined by measuring the concentration of total nitrite in the
culture supernatants (A) with Griess reagent (R & D Systems, Inc.). Lipid
peroxidation (LPO) in the control and STZ-treated cells was measured as total
amount of malonedialdehyde (B) as per the vendor’s protocol (Oxis Research, Inc.).
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant difference (*p≤0.05, **p ≤0.01) relative to the untreated control cells.
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3.1.3 Effects of STZ on cell survival and apoptosis
STZ-induced time- and concentration-dependent apoptosis in Rin-5F cells, as
detected by an increase in nuclear condensation, was observed by Hoechst staining
(Figure 16).
Figure 17A shows that increasing the time and concentration of STZ treatment
significantly increased the percentage of cells undergoing early/late apoptosis.
Treatment of Rin-5F cells with 1 mM STZ for 24 h caused 12% of cells to go into
late apoptosis, which increased to 22% in 10 mM STZ. Increasing the duration of
STZ treatment caused a further increase in the late apoptotic cells (almost 20% to
36% at 1 mM STZ and 10 mM STZ, respectively). The histogram in Figure 17A
represents the percentage of total apoptotic cells after treatment with STZ at different
concentrations and time intervals. This increase in apoptosis was also confirmed by
increased activity of caspase isoenzymes (8, 9 and 3) (Figure 17B). The activities of
extrinsic and intrinsic apoptotic enzymes caspase-8 and -9 significantly increased
with increasing time of treatment and concentration of STZ. However, the activities
of terminal apoptotic enzyme caspase-3 showed significant increase after treatment
with 10 mM STZ only at 24 h and 48 h.
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Figure 16: STZ-induced DNA fragmentation.
Staining of fragmented nuclei of STZ-treated and untreated cells was performed by
using Hoechst33342 dye. Cover slips with adherent cells were treated with STZ,
fixed with 3.7% formaldehyde and stained with Hoechst33342 (10 µg/ml) for 20 min
at room temperature. The cover slips were washed, mounted on glass slides and
analysed by fluorescence microscopy. Cells with signs of apoptosis showed
fragmented nuclei. Representative slides from three experiments are shown. Original
magnification X200.
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Figure 17: STZ-induced apoptosis.
Apoptosis was measured in Rin-5F cells treated with different concentrations of STZ
at different time intervals by flow cytometry using FACSCanto software.
Representative dot plots are shown and the percentage of apoptotic cells is
represented as a histogram (A). Activity of caspases was measured in cells (B)
treated with different concentrations of STZ at different time intervals
colorimetrically using the respective substrates as described in the vendor’s protocol
(R & D Systems, Inc.). Results are expressed as mean +/- SEM of three experiments.
Asterisks indicate significant differences (*p≤0.05, **p ≤0.01) relative to the
untreated control cells.
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3.1.4 Effect of STZ on the expression of apoptotic marker proteins
Figure 18A shows alterations in the expression of oxidative stress marker
proteins NOS-2 and Nrf2. The expression of NOS-2 was significantly increased by
increasing the concentration and the time interval of STZ treatment. In parallel, the
expression of Nrf2, the master regulator of the anti-oxidant protein, was significantly
decreased in concentration- and time-dependent manner after STZ treatment.
Increased phosphorylation of the cell signaling kinase, Akt, was observed at high
concentrations of STZ. A mild increase in GLUT2 expression was observed,
suggesting increased STZ/glucose uptake through this mechanism. Figure 18B shows
a marked cleavage of apoptotic marker protein caspase-3 as well as poly (ADPribose) polymerase (PARP) and alterations in the expression of intrinsic
mitochondrial specific proteins like Bcl-2 and Bax were also observed at high
concentrations. All these results confirm the increased oxidative stress and apoptosis
observed in these cells after STZ treatment.
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Figure 18: Expression of apoptotic protein markers.
Total extracts (30 µg protein) from control and Rin-5F cells treated with different
concentrations of STZ at different time intervals were separated on 12% SDS-PAGE
and transferred to nitrocellulose paper by Western blotting. NOS-2 Nrf2, Akt, p-Akt,
GLUT2 (A) and Caspase-3, PARP, Bax, and Bcl-2 proteins (B) were detected using
specific antibodies against these proteins. Beta-actin was used as a loading control.
The quantitation of protein bands are expressed as relative ratios normalised against
actin or other proteins as appropriate. The figures are representative of three
experiments. Asterisks indicate significant differences (*p≤0.05, **p ≤0.01) relative
to the untreated control cells
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Figure 18: Expression of apoptotic protein markers (continued).
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3.1.5 Effects of STZ on CYP 450 activities.
Isoenzyme-specific substrates were used to measure the microsomal activities
of CYP1A1 and CYP1A2 in Rin-5F cells treated with STZ at different
concentrations and time intervals. CYP1A1 activity showed significant increase with
10 mM STZ at 24 h and 48 h (Figure 19A), while no significant increase of enzyme
activity was observed with 1 mM STZ. CYP1A2 activity, on the other hand,
increased significantly (2-3 fold) at all concentrations and time points (Figure 19B).
These results may suggest the involvement of the CYP1A family of isoenzymes in
STZ metabolism.
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Figure 19: STZ-induced alteration in CYP activities.
CYP 1A1(A) and CYP 1A2 (B) activities were measured in Rin-5F cells treated with
different concentrations of STZ at different time intervals using the respective
substrates as described in the Materials and Methods. Results are expressed as mean
+/- SEM of three experiments. Asterisks indicate significant differences (*p≤0.05,
**p ≤0.01) relative to the untreated control cells.
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3.1.6 Effects of STZ on GSH/GSSG ratio and GSH metabolism
Concentration- and time-dependent decreases (60-70%) in the ratio of cellularreduced GSH and oxidised GSSG was observed after STZ treatment (Figure 20A).
However, a slight recovery in the GSH/GSSG ratio after 48h of treatment with the
lower concentration of STZ suggests some delay in recycling of oxidised GSSG.
The GSH-conjugating enzyme, GST, was significantly increased (almost 2fold) at high concentrations of STZ (Figure 20B). On the other hand, a marginal
increase was observed with 1 mM STZ at 48 h. A marked increase (about 6-8-fold)
in GSH-Px activity was also observed when cells were treated with 10 mM STZ both
at 24 h and 48 h (Figure 20C). Though statistically not significant, a marginal
increase in enzyme activity was also observed in cells treated with 1 mM STZ for 24
h. These results may suggest an increased cellular GSH-conjugation and
detoxification mechanism as an adaptation towards STZ metabolism and toxicity.
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Figure 20: STZ-induced alteration in GSH metabolism.
Rin-5F cells were treated with different concentrations of STZ for different time
intervals. GSH/GSSG ratio (A), GST (B) and GSH-Px (C) were measured. Results
are expressed as mean +/- SEM of three experiments. Asterisks indicate significant
differences (*p≤0.05, **p ≤0.01) relative to the untreated control cells.

71
3.1.7 Effects of STZ on mitochondrial respiratory function and ATP production
Figure 21 shows the effects of STZ treatment on mitochondrial respiratory
enzymes and bioenergetics. Both 1 mM and 10 mM STZ caused a significant
inhibition (40-50%) in NADH-ubiquinone oxidoreductase (Complex I) enzyme
activity after 24 h and 48 h (Figure 21A). The activity of succinate-cytochrome c
reductase (Complex II/III) was also significantly inhibited (40-65%) after 24 h and
48 h, with both 1 mM and 10 mM STZ (Figure 21B). The activity of the terminal
respiratory enzyme Complex IV was markedly inhibited (6-8 fold) by increasing the
concentration and time of STZ treatment (Figure 21C). Consistent with the reduction
in mitochondrial respiratory activity, ATP levels were also markedly decreased by
increasing the concentration and the time of STZ treatment (Figure 21D).
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Figure 21: STZ-induced alterations in mitochondrial enzyme activities.
Rin-5F cells were treated with different concentrations of STZ for different time
intervals. Respiratory Complex I (A), Complex II/II (B) and Complex IV (C) were
measured using their respective substrates as described in the Materials and Methods.
ATP content (D) was measured using the ATP bioluminescent somatic cell assay kit.
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant differences (*p≤0.05, **p ≤0.01) relative to the untreated control cells.
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Figure 21: STZ-induced alterations in mitochondrial enzyme activities (continued).

3.1.8 The mechanisms of induced-STZ cytotoxicity in Rin-5F cells
Figure 22 shows a schematic model depicting the mechanisms of STZ-induced
cytotoxicity in Rin-5F cells. STZ competes with glucose to enter the cells via GLUT2 receptors, causing Akt phosphorylation, which in turn causes further translocation
of the GLUT 2 receptors. STZ-induced cytotoxicity increased production of
ROS/NOS, lipid peroxidation and DNA damage, while decreasing the GSH/GSSG
ratio. Moreover, STZ induced mitochondrial dysfunction through inhibition of the
activities of the mitochondrial respiratory enzymes, Complex I, Complex II/III and
Complex IV, and decreased ATP production. STZ treatment induced apoptosis by
both the caspase-dependent pathway through the activation of caspases 3 and 9, and
the caspase-independent pathway by DNA fragmentation and PARP cleavage.
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Figure 22: Schematic model depicting the mechanisms of STZ-induced cytotoxicity
in Rin-5F cells.
STZ competes with glucose (Glu) to enter the cells via GLUT 2 receptors, causing
Akt phosphorylation, which in turn, causes further translocation of the GLUT 2
receptors. The model also shows that STZ induces cytotoxicity and apoptosis by
increased ROS/NOS production, oxidative/nitrosative stress, increased LPO, DNA
damage, a decreased GSH/GSSG ratio, and mitochondrial dysfunction. Upward
arrows (↑) indicate increase and downward arrows (↓) indicate decrease.
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3.2 Effect of NAC treatment on STZ-treated Rin-5F cells
3.2.1 Effect of NAC and STZ on Rin-5F cell viability
Based on the STZ studies, 10 mM STZ was chosen to investigate the
cytoprotective effect of NAC on STZ-induced cytotoxicity in Rin-5F cells. Cell
survival, measured by the mitochondrial enzyme-based MTT assay, showed that STZ
treatment caused about 40% reduction in cell viability (Figure 23). NAC pretreatment led to a significant recovery in cell survival in STZ-treated cells.

Figure 23: Effect of NAC and STZ on cell viability.
Rin-5F cells (~2  104) were grown in 96-well plates for 24 h and treated with STZ
with/without NAC. The formazan crystals that formed, following the reduction of
MTT by metabolically active (viable) cells, were solubilised in acidified isopropanol
and quantitated using the ELISA reader at 550 nm. Results are expressed as mean +/SEM for three experiments. Asterisks indicate significant differences (**p ≤0.01)
relative to the untreated control cells and the triangle (∆ p≤0.05) indicates significant
difference from STZ-treated cells.
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3.2.2 Effect of NAC on STZ-induced apoptosis
Rin-5F cells were treated with STZ with and without NAC, and apoptosis was
measured by FACS analysis. As shown in figure 24, a significant increase in the
percentage of cells undergoing early/late apoptosis (̴ 25%) was observed with 10mM
STZ treatment for 24 h compared to the control untreated cells (~3-5%). NAC pretreatment resulted in a remarkable reduction in apoptotic cell death in STZ-treated
cells, suggesting that NAC protects against cell death.

Figure 24: Effect of NAC on apoptosis.
Apoptosis was measured in Rin-5F cells treated with STZ with/without NAC as
described before in the Materials and Methods by flow cytometry using FACSDiva
software. Representative dot plots are shown and the percentage of apoptotic cells is
represented as a histogram. Results are expressed as mean +/- SEM of at least three
experiments. Asterisks indicate significant differences (**p ≤0.01) from control
untreated cells and triangles (∆∆ p ≤0.001) indicate significant differences from
STZ-treated cells.
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3.2.3 Effect of NAC on STZ-induced oxidative stress
Rin-5F cells were treated with STZ and/or NAC and assays were performed to
measure the oxidative stress. Significant increases in intracellular ROS production
(Figure 25A), NO production (Figure 25B) and lipid peroxidation as measured by
malondialdehyde (MDA) levels (Figure 25C) were observed after STZ treatment.
NAC pre-treatment, on the other hand, caused a remarkable reduction in ROS
production and lipid peroxidation. However, NO production was only marginally
affected after NAC treatment.

Figure 25: Effect of NAC on ROS, NO and LPO.
Rin-5F cells were cultured to 70-80% confluence and treated with STZ with/without NAC as
described in the Materials and Methods. ROS production was measured in cell lysate using
DCFDA and fluorescence was measured by flow cytometry using FACSDiva software as
described before [221]. The histogram represents percentage change in ROS production (A).
NO production was determined by measuring the concentration of total nitrite in the culture
supernatants (B) with Griess reagent (R & D Systems Inc.). Lipid peroxidation (LPO) was
measured as the total amount of malonedialdehyde (C). Results are expressed as mean +/SEM of at least three experiments. Asterisks indicate significant differences (**p ≤0.01)
from control untreated cells and triangles (∆∆ p ≤0.01) indicate significant differences from
STZ-treated cells
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Figure 25: Effect of NAC on ROS, NO and LPO (continued).
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3.2.4 Effect of NAC on GSH metabolism in STZ-treated cells
Since NAC is a glutathione precursor, we investigated the effects of STZ/NAC
on GSH levels by measuring the ratio of reduced to oxidised GSH, as well as on the
enzymes involved in regulating GSH metabolism. A significant reduction in
GSH/GSSG ratio (70%) was observed after STZ treatment in Rin-5F cells (Figure
26A). NAC pre-treatment led to a moderate recovery in GSH levels. The activity of
GSH-Px was significantly increased in STZ-treated cells (Figure 26B). This could be
due to the increased oxidative stress and increase in peroxide levels. NAC pretreatment, however, caused a significant reduction in the enzyme activity. On the
other hand, the activity of GSH reductase, which catalyses the reduction of the
oxidised glutathione, was significantly reduced in STZ-treated cells, explaining the
low ratio of GSH/GSSG (Figure 26C). However, pre-treatment with NAC brought
about a significant recovery of the activity of the enzyme.
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Figure 26: Effect of NAC on GSH metabolism.
GSH/GSSG ratio (A), GSH-Px (B) and GSH reductase (C) were measured as
described before in the Materials and Methods. Results are expressed as mean +/SEM of three experiments. Asterisks indicate significant differences (**p ≤0.01)
from control untreated cells and triangles (∆ p≤0.05, ∆∆ p ≤0.01) indicate significant
differences from STZ-treated cells.
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3.2.5 Effect of NAC on mitochondrial bioenergetics
3.2.5.1 Effect of NAC on mitochondrial membrane potential (MMP)
The role of mitochondrial membrane potential (MMP) is very important in
determining the fate of cells undergoing oxidative stress and mitochondrial
dysfunction. Disturbances in the membrane potential result in the opening of the
mitochondrial pores, thus releasing cytochrome c into the cytosol, which
subsequently triggers the downstream apoptotic cascade. Our results showed a
significant loss in the membrane potential after treatment with STZ in Rin-5F cells
(Figure 27). NAC pre-treatment, however, led to a significant recovery of the MMP
in STZ-treated cells.
3.2.5.2 Effect of NAC on mitochondrial enzyme activity
The activities of the mitochondrial respiratory complexes, as well as of the
Krebs’ cycle enzyme aconitase, are sensitive indicators of mitochondrial
bioenergetics and oxidative stress. As shown in Figure 28 (A, B), STZ treatment
caused a significant reduction in the activities of Complex I and Complex IV. NAC
pre-treatment, however, brought about only a marginal recovery in the activity of
Complex IV but not in the activity of Complex I. NAC appeared to exhibit some
inhibitory effect on the Complex I activity presumably affecting the availability of
the substrate (e.g. NADH) or the glutathionylation of this enzyme, resulting in the
alteration of the enzyme activity. Similarly, a marked inhibition (90%) was also
observed in the activity of aconitase, a ROS-sensitive mitochondrial matrix enzyme,
after STZ treatment (Figure 28C). NAC pre-treatment caused a significant recovery
in the activity. Also, NAC treatment alone showed a significant activation of this
enzyme. This may be due to the scavenging of endogenous ROS production by NAC.

82

Figure 27: Effect of NAC on mitochondrial membrane potential.
Mitochondrial membrane potential (Δψm) was measured by flow cytometry using a
fluorescent cationic dye according to the vendor’s protocol (DePsipheTM, R &D
System, Inc.). A typical histogram representing the percentage loss of mitochondrial
membrane potential is shown. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (*p ≤0.05, **p ≤0.01) from
control untreated cells and triangles (∆∆ p ≤0.01) indicate significant differences
from STZ-treated cells.
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Figure 28: Effect of NAC on mitochondrial enzyme activities.
Activities of mitochondrial respiratory enzyme complexes, (Complex I (A), Complex
IV (B)), and the matrix enzyme, aconitase (C), were measured using their respective
substrates as described in the Materials and Methods. Results are expressed as mean
+/- SEM of three experiments. Asterisks indicate significant differences (**p ≤0.01)
from control untreated cells and triangles (∆∆ p ≤0.01) indicate significant
differences from STZ-treated cells.
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3.2.6 Effect of NAC on glutamate dehydrogenase and hexokinase activities
Glutamate dehydrogenase is a mitochondrial matrix enzyme, which plays a key
role in nitrogen and glutamate metabolism and energy homeostasis. Figure 29A
shows a significant inhibition in the activity of glutamate dehydrogenase after STZ
treatment. However, pre-treatment with NAC brought only a marginal recovery.
Similarly, the activity of another key enzyme, hexokinase, required for glucose
metabolism and hormonal regulation, was also significantly inhibited (̴ 60%) after
STZ treatment (Figure 29B). NAC treatment, however, did not assist in recovering
the activity back to the normal control level.
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Figure 29: Effects of NAC on glutamate dehydrogenase and hexokinase activities.
Glutamate dehydrogenase (A) and hexokinase (B) enzyme activities were measured
by a coupled enzyme assay method as mentioned in the Materials and Methods.
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant differences (**p ≤0.01) from control untreated cells.
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3.2.7 Effect of NAC treatment on insulin levels
Assessment of insulin levels and its secretion has been a useful guide to
determine the therapeutic efficacy and management in diabetic patients. In our study,
we observed a significant decrease in the amount of insulin after STZ treatment
(Figure 30). NAC pre-treatment, however, did not restore the insulin level in STZtreated cells, while a moderate increase in insulin level was observed in control cells
treated with NAC alone.

Figure 30: Effect of NAC on insulin level.
Insulin levels were measured using the Fluorescence Resonance Energy Transfer
(FRET) method by using two different anti-insulin antibodies as mentioned in the
Materials and Methods. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (**p ≤0.01) from control
untreated cells.
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3.2.8 Effect of NAC on the expression of oxidative stress and apoptotic protein
markers
In cells, the increased oxidative stress also triggers a cascade of signaling
events, including cleavage of caspases leading to apoptosis. As shown in Figure 31A,
STZ treatment increased the cleavage of molecular oxidative stress and apoptotic
marker proteins such as PARP, iNOS, caspase-3 and caspase-9. NAC pre-treatment
showed a moderate to significant reduction in the cleavage of PARP, caspase-3 and
caspase-9, demonstrating protection against the oxidative stress induced by STZ. On
the other hand, no significant effect on increased iNOS expression was observed
after NAC treatment. This also confirmed the effect of NAC on the NO level
measured in STZ-treated cells (Figure 25B). Treatment with STZ also increased the
expression of the pro-apoptotic protein, Bax, and decreased the expression of antiapoptotic protein, Bcl-2, (Figure 31B). NAC pre-treatment again significantly
decreased the expression ratio of the Bax/Bcl-2, reconfirming its protective effects
against STZ-induced toxicity.
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Figure 31: Expression of oxidative stress and apoptotic protein markers.
Total protein extracts (30 µg) from control and STZ-treated cells were separated on
12% SDS-PAGE. PARP, iNOS, caspase-3, caspase-9 (A) Bax, and Bcl-2 (B),
proteins were detected using specific antibodies against these proteins. Beta-actin
was used as loading control. The quantitation of the protein bands are expressed as
relative ratios normalised against actin or other specific proteins as appropriate. The
figures are representative of three experiments. Asterisks indicate significant
differences (**p ≤0.001) from control untreated cells and triangles (∆ p≤0.05, ∆∆ p
≤0.01) indicate significant differences from STZ-treated cells.

89

Figure 31: Expression of oxidative stress and apoptotic protein markers (continued).
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Figure 32: Schematic model representing the cytoprotective mechanisms of NAC in
STZ treated Rin-5F cells.
As demonstrated in our previous study [238], STZ induces cytotoxicity and apoptosis
by increased ROS/NOS production and LPO and decreased GSH/GSSG ratio and
mitochondrial dysfunction. The schematic model shows the restoration of redox
homeostasis, GSH metabolism and mitochondrial bioenergetics after NAC treatment
in STZ-treated Rin-5F cells. Upward arrows (↑) indicate increase and downward
arrows (↓) indicate decrease.
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The study was then extended to investigate the effect of STZ-induced toxicity in the
presence of high glucose concentrations in Rin-5F cells. We attempted to compare
the net effect of STZ-induced toxicity in Rin-5F cells under normal and
hyperglycemic conditions.

3.3 Effect of streptozotocin treatment under high glucose conditions
3.3.1 Effect of streptozotocin treatment on cell viability in cells treated with high
glucose concentrations in comparison with normal glucose-treated cells

The MTT-based viability assay in Figure 33A shows that STZ inhibits Rin-5F
cell survival in the presence of normal glucose in a concentration- and timedependent manner, which confirms our previous study [238]. No significant
inhibition was observed after treatment with 1mM to 5 mM STZ for 2 h, though a
marginal inhibition (10-15%) in cell viability was observed after treatment with 10
mM STZ. On the other hand, significant inhibition was observed after 12 h of STZ
treatment. Figure 33B shows the effect of STZ on cell viability in the presence of
high amounts of glucose. As shown, a significant inhibition of viability was observed
within 2 h of 10 mM STZ treatment. In comparison with normal levels of glucose,
the inhibition of cell viability was more pronounced in the presence of high glucose.
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Figure 33: Effect of STZ treatment on cell survival under normoglycaemic and
hyperglycaemic conditions.
Rin-5F cells (~2 x 104) were treated with different concentrations of STZ (0-10 mM)
for different time intervals in the presence of normal glucose (A) and high glucose
(B) and cell viability measured as formazan formation at 550 nm. The results are
expressed as mean +/- SEM of three independent experiments. The asterisks indicate
significant differences (*p≤0.05, **p≤0.01, ***p≤0.001) compared with the control
cells treated with vehicle alone.
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3.3.2 Effect of STZ on apoptosis under hyperglycaemic conditions
Figure 34 shows the FACS analysis of cellular death/apoptosis after STZ
treatment on Rin-5F cells. Apoptosis was increased (10-20%) when cells were
treated with STZ for 24 h and 48 h in the presence of high glucose. No significant
changes were observed with high glucose alone. Cells treated with normal glucose
were used as the control for high glucose treated cells and cells treated with vehicle
alone in high glucose medium were used as the control for the STZ-treated cells.

Figure 34: Effect of STZ on apoptosis under hyperglycaemic conditions.
Apoptosis was measured in high glucose STZ-treated Rin-5F cells by FACS analysis
(A) according to the vendor’s protocol as described before [238]. Histogram (B)
shows percentage of viable, early apoptotic, late apoptotic and dead cells.
Representative dot plots from three experiments are shown.
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3.4 High glucose/high palmitic acid-induced cytotoxicity in Rin-5F cells
3.4.1 Effect of high glucose/high palmitic acid on Rin-5F cell viability
Significant alterations in mitochondrial dehydrogenase-based cell survival
were observed at high concentrations of palmitic acid after 24 h of treatment in the
presence of normal glucose (Figure 35A). Maximum inhibition was observed in cells
treated with 0.3-0.5 mM palmitic acid (~ 56% and 74%, respectively). Negligible
toxicity was observed using palmitic acid at concentrations below 0.06 mM. Around
30 - 40 % toxicity was observed at 0.08 mM- and 0.1 mM palmitic acid, respectively.
We further studied the effect of different concentrations of palmitic acid at
different time intervals on Rin-5F cells in the presence of normal and high glucose.
Cells were treated for different time intervals (2, 18, 24 and 48 h) with high
concentrations of palmitic acid (0.1, 0.3 and 0.5 mM) (Figure 35B). Maximum
inhibition of cell viability was observed with 0.3-0.5 mM palmitic acid at 24-48 h.
For further studies, we have selected only 0.06 mM and 0.3 mM palmitic acid since
0.5 mM was found extremely toxic with low yield of cells for further processing.
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Figure 35: Cell viability assays by MTT after treatment with different concentrations
of palmitic acid under normal and high glucose conditions.
Rin-5F cells were grown in 96-well plates. Cells were treated with: (A) different
concentrations of palmitic acid (0.02-0.5 mM) under normal glucose conditions for
24 h, (B) different concentrations of palmitic acid (0.1-0.5 mM) for different time
intervals (2-48h) under normal and high glucose conditions. Results are expressed as
mean +/- SEM of three experiments. Asterisks indicate significant differences
(*p≤0.05, **p ≤0.01, ***p ≤0.001) relative to untreated control cells under normal
glucose condition, and triangles indicate significant differences (Δp≤0.05, ΔΔp
≤0.01, ΔΔΔp ≤0.001) relative to untreated control cells under high glucose condition.
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3.4.2 Effect of high glucose/high palmitic acid treatment on oxidative stress
Treatment with palmitic acid showed a concentration-dependent increase in
intracellular ROS production under normal and high glucose conditions. ROS was
measured and captured microscopically using DCFDA. Maximum fluorescence was
observed with high concentration of palmitic acid (0.3 mM) under both normal as
well as high glucose conditions (Figure 36A). Intracellular ROS production was also
measured fluorometrically (Figure 36B) and by flow cytometry using the BD
FACSDiva software (Figure 36C). The higher concentration of palmitic acid (0.3
mM) showed a remarkable increase in ROS production (5-fold and 1.5-fold
compared with the control of normal and high glucose conditions, respectively) as
measured by FACS analysis.
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Figure 36: High glucose/ high palmitic acid-induced ROS production.
Intracellular production of ROS was measured in Rin-5F cells treated with
concentrations of palmitic acid under normal and high glucose conditions using the
cell permeable probe, DCFDA. (A) Cells were grown on cover slips and incubated
with 5 µM DCFDA for 30 min at 37 ° C. Cells were washed twice with PBS, and
fluorescence was immediately visualised using an Olympus fluorescence
microscope. Original magnification ×200. Production of ROS was also measured
fluorometrically (B) and by flow cytometry (C) using FACSDiva software as
described before in the Materials and Methods. Results are expressed as mean +/SEM of three experiments. Asterisks indicate significant differences (*p≤0.05, **p
≤0.01, ***p ≤0.001) relative to untreated control cells under normal glucose
condition, and triangles indicate significant differences (Δp≤0.05, ΔΔp ≤0.01, ΔΔΔp
≤0.001) relative to untreated control cells under high glucose condition.
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Figure 36: High glucose/ high palmitic acid-induced ROS production (continued).
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NO production was significantly increased (~ 50%) in Rin-5F cells treated with
0.06 mM palmitic acid under normal as well as high glucose conditions (Figure
37A). On the other hand, 0.3 mM palmitic acid showed a slight reduction in NO
production. In parallel with ROS production, LPO was significantly increased in a
concentration-dependent manner after treatment with palmitic acid under normal and
high glucose conditions (Figure 37B). Treatment with 0.3 mM palmitic acid under
high glucose conditions caused a remarkable increase (~2-fold) in malonedialdehyde
(MDA) production.
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Figure 37: High glucose/high palmitic acid-induced NO production and lipid
peroxidation in Rin-5F cells.
NO production was determined by measuring the concentration of total nitrite in the
culture supernatants (A) with Griess reagent. Lipid peroxidation (LPO) was
measured as the total amount of malonedialdehyde (B) as per the vendor’s protocol.
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant differences (**p ≤0.01, ***p ≤0.001) relative to untreated control cells
under normal glucose condition, and triangles indicate significant differences (ΔΔp
≤0.01, ΔΔΔp ≤0.001) relative to untreated control cells under high glucose condition.
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Also, a significant increase in the total NADPH oxidase-dependent ROS
formation (NOX) was observed with palmitic acid treatment under high glucose
conditions (Figure 38A). Palmitic acid treatment also showed an increase in
mitochondrial ROS formation (~40 %) in the presence of high glucose but no
significant alterations in normal glucose-treated cells (Figure 38B).

Figure 38: High glucose/high palmitic acid-induced NADPH oxidase (NOX)
activity.
Total NOX (A) and mitochondrial NOX (B) production was measured using the
lucigenin-enhanced chemiluminescence method and read using the Turner Designs
TD-20/20 luminometer. Results are expressed as mean +/- SEM of three
experiments. Triangles indicate significant differences (ΔΔp ≤0.01, ΔΔΔp ≤0.001)
relative to untreated control cells under high glucose condition.
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3.4.3 Effect of high glucose/high palmitic acid treatment on SOD and catalase
activity

SOD activity was significantly increased in the presence of high amounts of
glucose, which further increased with palmitic acid treatment (Figure 39A). Under
normal glucose conditions, 0.06 and 0.3 mM palmitic acid caused ~45% and 68%
increase in SOD activity, respectively. Comparatively, under high glucose
conditions, a ~15-25% increase in SOD activity was observed after palmitic acid
treatment. The increased in SOD activity could be due to the increase in superoxide
production, which in turn contributed to the increase in ROS production.
Figure 39B shows that the presence of palmitic acid caused a concentrationdependent increase in catalase activity under normal and high glucose conditions.
Furthermore, the effect of high glucose significantly increased the catalase activity
compared with normal glucose. The increase in catalase activity could be to clear the
excess of hydrogen peroxide produced by the increase in SOD activity.
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Figure 39: High glucose/high palmitic acid treatment-induced alterations in the
superoxide (SOD) and catalase enzyme activities.
Rin-5F cells were treated with different concentrations of palmitic acid under normal
and high glucose conditions as described in Materials and Methods. SOD (A) was
measured as percentage conversion of NBT to NBT-diformazan according to the
vendor’s protocol. The percentage reduction in formazan formation was used as a
measure of SOD activity. Catalase measurement (B) was dependent on its ability to
catalyse the oxidation of alcohol such as methanol by hydrogen peroxide and the
formaldehyde produced was measured colorimetrically. Results are expressed as
mean +/- SEM of three experiments. Asterisks indicate significant differences
(*p≤0.05, **p ≤0.01) relative to untreated control cells under normal glucose
condition, and triangles indicate significant differences (Δp≤0.05, ΔΔΔp ≤0.001)
relative to untreated control cells under high glucose condition.
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3.4.4 Effect of high glucose/high palmitic acid on mitochondrial bioenergetics
3.4.4.1 Mitochondrial enzymes activity
Figure 40 shows the effects of high glucose/high palmitic acid treatment on the
activities of mitochondrial respiratory enzyme complexes and the mitochondrial
matrix enzyme aconitase. The palmitic acid treatment provoked a concentrationdependent increase in the activities of complex I, II/III and IV (Figure 40A, B and C,
respectively) under normal glucose conditions. However, in the presence of high
levels of glucose, palmitic acid treatment suppressed the activities of the
mitochondrial respiratory complexes. Significant reduction of the mitochondrial
complex I and IV enzymes was observed with 0.3 mM palmitic acid at high glucose
concentration.
A significant reduction (~44%) in the activity of aconitase, a ROS-sensitive
mitochondrial matrix enzyme, was observed after treatment with high concentration
of palmitic acid (0.3 mM) under normal glucose conditions (Figure 40D). On the
other hand, 0.06 mM palmitic acid had no significant effect on the activity of
aconitase both at normal glucose and high glucose concentrations. However, the
activity was significantly inhibited with 0.3 mM palmitic acid under normal glucose
condition. While high glucose treatment itself caused a moderate decrease in
aconitase activity when compared with the normal glucose treatment, the palmitic
acid treatment in the presence of high glucose did not further reduce the aconitase
activity. This shows that the high glucose concentration might play a role in
protecting aconitase against the deteriorating effects of palmitic acid.
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Figure 40: High glucose/high palmitic acid treatment-induced alterations in
mitochondrial enzyme activities.
Rin-5F cells were treated with (0.06-0.3 mM) palmitic acid under normal and high
glucose conditions. Respiratory complex I (A), complex III (B) and complex IV (C)
and aconitase (D) were measured as described before in Materials and Methods.
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant differences (*p≤0.05, **p ≤0.01, ***p ≤0.001) relative to untreated
control cells under normal glucose condition, and triangles indicate significant
differences (Δp≤0.05, ΔΔp ≤0.01) relative to untreated control cells under high
glucose condition.
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Figure 40: High glucose/high palmitic acid treatment-induced alterations in
mitochondrial enzyme activities (continued).
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3.4.4.2 ATP production
As observed in figure 41, the palmitic acid treatment caused a significant
inhibition (~24-40%) in ATP production in a concentration-dependent manner under
normal glucose conditions. However, under high glucose condition, significant
inhibition in ATP was observed only with 0.3 mM of palmitic acid. High glucose
alone also caused a decrease in ATP production, suggesting an adaptation in energy
metabolism against the excessive availability of energy nutrients.

Figure 41: High glucose/high palmitic acid treatments inhibit ATP production.
Rin-5F cells were treated with different concentrations of palmitic acid in the
presence of normal and high glucose and ATP content was measured using the ATP
bioluminescent somatic cell assay kit. Results are expressed as mean +/- SEM of
three experiments. Asterisks indicate significant differences (*p≤0.05) relative to
untreated control cells under normal glucose condition, and triangles indicate
significant differences (Δp≤0.05) relative to untreated control cells under high
glucose condition.
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3.4.4.3 Mitochondrial membrane potential (MMP)
The mitochondrial membrane potential (MMP) plays a crucial role in
determining the mitochondrial bioenergetics and fate of the cells under conditions of
oxidative stress and availability of excess nutrients. Disturbances in the membrane
potential disturb the ATP production and result in the opening of the mitochondrial
pores, thus triggering the apoptotic cascade. Significant loss in the membrane
potential was observed after treatment with palmitic acid in the presence of both
normal and high glucose in a concentration-dependent manner (Figure 42).
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Figure 42: High glucose/high palmitic acid treatment induced alteration in the
mitochondrial membrane potential.
Mitochondrial membrane potential (Δψm) was measured by flow cytometry (A)
using a fluorescent cationic dye according to the vendor’s protocol. A typical
histogram (B) representing the percentage loss of mitochondrial membrane potential
is shown. Results are expressed as mean +/- SEM of three experiments. Asterisks
indicate significant differences (**p ≤0.01, ***p ≤0.001) relative to untreated control
cells under normal glucose condition, and triangles indicate significant differences
(ΔΔp ≤0.01) relative to untreated control cells under high glucose condition.
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3.4.5 Effect of high glucose/high palmitic acid treatment on apoptosis
3.4.5.1 DNA fragmentation and Hoechst staining
As shown in Figure 43A, palmitic acid treatment caused a concentrationdependent increase in DNA fragmentation under normal as well as high glucose
conditions, though it was more pronounced under high glucose condition.
Consistently, an increase in nuclear condensation was also detected by Hoechst
staining with higher concentration of palmitic acid in the presence of normal and
high glucose (Figure 43B).

Figure 43: High glucose/high palmitic acid induced DNA fragmentation.
Rin-5F cells were grown to confluence and treated with different concentrations of
palmitic acid in the presence of normal and high glucose. DNA fragmentation was
analysed by agarose gel (2%) electrophoresis and ethidium bromide staining (A). In
some cases, cells were grown on cover slips. Staining of fragmented nuclei of treated
cells was performed by using Hoechst33342 dye (B). Cover slips with adherent cells
were treated with different concentrations of palmitic acid in the presence of normal
and high glucose conditions, fixed with 3.7% formaldehyde and stained with
Hoechst33342 (10 µg/ml) for 20 min at room temperature. The cover slips were
washed, mounted on glass slides and analysed by fluorescence microscopy. Cells
with signs of apoptosis showed fragmented nuclei. Representative slides from three
experiments are shown. Original magnification X200

111

Figure 43: High glucose/high palmitic acid induced DNA fragmentation (continued).

3.4.5.2 Flow cytometry
A significant concentration-dependent increase in the percentage of cells
undergoing early/late apoptosis was detected, consistent with DNA fragmentation in
the presence of high glucose and high palmitic acid. The histogram in Figure 44
shows the percentage of apoptotic cells after palmitic acid treatment of Rin-5F cells
under normal and high glucose conditions.
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Figure 44: High glucose/high palmitic acid treatment-induced apoptosis.
Apoptosis was measured in Rin-5F cells treated with different concentrations of
palmitic acid under normal and high glucose conditions by flow cytometry using
FACSDiva software. Representative dot plots are shown and percentage of apoptotic
cells is represented as a histogram. Results are expressed as mean +/- SEM of three
experiments.
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3.4.5.3 Caspase activities
The concentration-dependent increase in apoptosis was further confirmed by
the increase in the activities of caspase-3 and -9 enzymes (Figure 45). A significant
increase in caspase activity was observed with 0.06 mM palmitic acid. This further
increased with 0.3 mM palmitic acid. The presence of high amounts of glucose in the
media aggravated the activities of the enzymes.

Figure 45: High glucose/high palmitic acid-induced increase in the activities of
caspase-3 and -9.
Activities of caspases were measured in treated cells colorimetrically using the
respective substrates as described in Materials and Methods. Results are expressed as
mean +/- SEM of three experiments. Asterisks indicate significant differences
(*p≤0.05) relative to untreated control cells under normal glucose condition, and
triangles indicate significant differences (Δp≤0.05, ΔΔp ≤0.01) relative to untreated
control cells under high glucose condition.
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3.4.6 Effect of high glucose/high palmitic acid treatment on energy metabolism
enzyme activities

Glutamate dehydrogenase (GDH) is a mitochondrial matrix enzyme, which
catalyses the reversible oxidative deamination of L-glutamate into α-ketoglutarate
and ammonia using NAD (P)+ as coenzyme [239]. It is regulated by the energy status
of the cells. As shown in Figure 46A, palmitic acid treatment caused a significant
decrease (~30- 60%) in the GDH activity in a concentration-dependent manner under
normal glucose conditions. Similarly, under high glucose conditions, high
concentration of palmitic acid diminished the activity of GDH (~20% inhibition with
0.3 mM palmitic acid compared with control high glucose). However, in the presence
of high glucose concentration, the low concentration of palmitic acid (0.06 mM)
increased the activity of GDH, by ~24% compared with control high glucose.
Similarly, high concentration of palmitic acid (0.3 mM) caused a significant
decrease (~27-22%) in the activity of hexokinase (HK), the initial and rate-limiting
enzyme of glycolysis, in the presence of normal glucose as well as high glucose,
respectively (Figure 46 B). High glucose concentration alone appeared to activate the
HK enzyme, presumably due to increased glucose uptake and as a mechanism of
compensation for the excess glucose in the medium, which was not altered
appreciably after a low concentration of palmitic acid.
The activity of G6PDH was markedly reduced in a concentration-dependent
manner by palmitic acid in the presence of normal glucose and high glucose (Figure
46 C). The inhibitory effect was more pronounced under high glucose conditions.
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Figure 46: High glucose/high palmitic acid treatment-induced alterations in
glutamate dehydrogenase, hexokinase and glucose-6-phosphate dehydrogenase
enzymes.
The activity of glutamate dehydrogenase (A) hexokinase (B) and G6PDH enzyme
(C) was measured by a coupled enzyme assay method as mentioned in the Materials
and Methods. Results are expressed as mean +/- SEM of three experiments. Asterisks
indicate significant differences (*p≤0.05, ***p ≤0.001) relative to untreated control
cells under normal glucose condition, and triangles indicate significant differences
(Δp≤0.05, ΔΔΔp ≤0.001) relative to untreated control cells under high glucose
condition.
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3.4.7 Effect of high glucose/high palmitic acid treatment on GSH metabolism
Figure 47A shows the inhibitory effect of palmitic acid on the GSH/GSSG
ratio, in concentration-dependent manner, in the presence of normal and high glucose
conditions. The inhibitory effect of palmitic acid was more pronounced in the
presence of high amounts of glucose.
In parallel, the activity of the GSH reductase was significantly decreased with
high concentration of palmitic acid in the presence of high glucose (Figure 47B),
suggesting a reduction in the recycling mechanism, thus causing an increase in
oxidised GSSG. Palmitic acid seems to have no appreciable effects on GSHreductase activity in normal glucose-treated cells.
As observed in Figure 47C, palmitic acid evidently reduced the activity of
GSH-Px under normal and high glucose conditions. The activity of GSH-conjugating
enzyme, GST, was slightly decreased with high concentrations of palmitic acid in the
presence of normal glucose (Figure 47D). These results may suggest the reduced
availability of GSH and a compromised detoxification mechanism in Rin-5F cells
treated with high glucose/high palmitic acid.
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Figure 47: High glucose/ high palmitic acid-induced alterations in GSH metabolism.
Rin-5F cells were treated with different concentrations of palmitic acid under normal
and high glucose conditions; GSH/GSSG ratio (A), GSH reductase (B), GSH-Px (C)
and GST (D) were measured. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (*p≤0.05, **p ≤0.01, ***p
≤0.001) relative to untreated control cells under normal glucose condition, triangles
indicate significant differences (Δp≤0.05, ΔΔp ≤0.01, ΔΔΔp ≤0.001) relative to
untreated control cells under high glucose condition.
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Figure 47: High glucose/ high palmitic acid-induced alterations in GSH metabolism
(continued).
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3.4.8 Effect of high glucose/high palmitic acid treatment on insulin levels
Insulin is a critical regulator of metabolism. It is secreted in response to
changes in plasma glucose and concentration of energy nutrients. In addition to
glucose, some amino acids and fatty acids also regulate insulin release [240]. As
shown in Figure 48, treatment with low concentration of palmitic acid in the
presence of normal glucose caused a 50% increase in insulin level, while high
concentration of palmitic acid caused a slight decrease in insulin level (11%). A
similar trend was found under high glucose conditions, with 0.06 mM palmitic acid
causing a 13% increase in insulin level while 0.3 mM palmitic acid caused almost a
40% reduction in insulin level.

Figure 48: High glucose/high palmitic acid treatment-induced alterations in insulin
levels.
Insulin levels were measured using the Fluorescence Resonance Energy Transfer
(FRET) method by using two different anti-insulin antibodies as mentioned in the
Materials and Methods. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (*p≤0.05) relative to untreated
control cells under normal glucose condition.
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3.4.9 Effects of high glucose/high palmitic acid treatment on the release of
inflammatory cytokines in Rin-5F cells

Figure 49A shows the effect of palmitic acid treatment, under normal and high
glucose conditions, on the levels of 12 cytokines [IL 1α, IL 1β, IL2, IL4, IL 6, IL10,
IL12, IL13, IFN-γ, TNF-α, GM-CSF, RANTES] using a multi-analyte ELISA array
kit. It was observed that 0.06 mM palmitic acid dramatically increased the levels of
almost all the tested cytokines.
On the basis of the multi-analyte array, further experiments were conducted to
investigate the effect of palmitic acid treatment on the level of TNF-α, the primary
regulator of inflammatory response, and IL6, which has pro- and anti-inflammatory
responses, using sandwich ELISA kits. Results similar to those found using the
multi-array were observed, as shown in Figure 49B and 49C. A significant increase
in the levels of TNF-α and IL-6 were observed with 0.06 mM palmitic acid
compared with the 0.3 mM treatment. A pronounced increase (about 3-fold) in TNFα levels was observed with 0.06 mM palmitic acid compared with 0.3 mM palmitic
acid, which showed a mild increase under normal glucose condition. However, in the
presence of high glucose the levels of TNF-α increased with both concentrations of
palmitic acid (Figure 49B).
Similar effects were observed with IL-6 levels after palmitic acid treatment. A
significant increase was observed with 0.06 mM palmitic acid under normal as well
as high glucose conditions. On the other hand, 0.3 mM palmitic acid caused a
significant increase only in the presence of high glucose (Figure 49C).
Moreover, palmitic acid treatment caused a concentration-dependent increase
in prostaglandine E2 (PGE2) levels under both normal and high glucose conditions
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(Figure 49D).

Figure 49: High glucose/high palmitic acid-induced alterations in cytokine levels.
Rin-5F cells were cultured to confluence and treated with different concentrations of
palmitic acid. Microarray (A), TNF-α (B), IL-6 (C) and PGE2 (D) were measured
using standard ELISA kits as described earlier in Materials and Methods. Results are
expressed as mean +/- SEM of three experiments. Asterisks indicate significant
differences (*p≤0.05, ***p ≤0.001) relative to untreated control cells under normal
glucose condition, triangles indicate significant differences (ΔΔp ≤0.01, ΔΔΔp
≤0.001) relative to untreated control cells under high glucose condition.
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Figure 49: High glucose/high palmitic acid-induced alterations in cytokine levels
(continued).
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3.4.10 Effect of high glucose/high palmitic acid treatment on the expression level
of apoptotic, autophagic, inflammatory and cell signalling markers

Figure 50A shows alterations in the expression of apoptotic markers for
intrinsic mitochondrial specific proteins such as Bcl-2 and Bax in concentrationdependent manner with palmitic acid treatment in the presence of normal glucose
and high glucose. Similar alterations were also observed in the levels of
mitochondrial cytochrome c. The level of mitochondrial cytochrome c content was
decreased after treatment with high palmitic acid. High concentration of palmitic
acid, in the presence of normal as well as high glucose conditions, increased the
cleavage of PARP as well as that of caspase3.
In consistence, a 30% decrease in the expression of the autophagic proteins,
Atg5 and LC3II, was observed with high concentration of palmitic acid under normal
as well as high glucose conditions, with concomitant increase in the phosphorylation
of mTOR, autophagic inhibitor (Figure 50B).
Decreased phosphorylation of AMPK, the central regulator of cell energy
hemostasis and metabolism, was observed in concentration-dependent manner under
lipotoxic and glucolipotoxic conditions (Figure 50C). Similarly, decreased
phosphorylation of JNK was observed in concentration-dependent manner under
both conditions. A low concentration of palmitic acid caused an increase in the
phosphorylation of the cell signalling kinase Akt under both normal as well as high
glucose conditions (Figure 50C).
A substantial increase in oxidative stress and inflammatory signal protein, NFkB, nuclear translocation was observed after treatment with palmitic acid in
concentration-dependent manner under normal and high glucose conditions (Figure
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50D). These results further suggest and support the activation of apoptosis,
inflammation and increased oxidative stress in glucolipotoxicity.

Figure 50: High glucose/high palmitic acid treatment-induced alterations in the
expression of apoptotic, autophagic, signalling and inflammatory proteins.
Total extracts (30 µg protein) from treated cells were separated on 12% SDS-PAGE
and transferred on to nitrocellulose paper by Western blotting. Bax/Bcl-2, Mito cyt c,
PARP and caspase-3 (A) Atg5, LC3 and mTOR (B), AMPK, JNK and Akt (C) and
NF-kB (D) proteins were detected using specific antibodies against these proteins.
Beta-actin was used as loading control. The quantitation of the protein bands are
expressed as relative ratios normalised against actin or other specific proteins as
appropriate. The figures are representative of three experiments. Asterisks indicate
significant difference (*p≤0.05, **p ≤0.01) relative to untreated control cells under
normal glucose condition, (Δp≤0.05, ΔΔp ≤0.01) relative to untreated control cells
under high glucose condition.
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Figure 50: High glucose/high palmitic acid treatment-induced alterations in the
expression of apoptotic, autophagic, signalling and inflammatory proteins
(continued).
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Figure 50: High glucose/high palmitic acid treatment-induced alterations in the
expression of apoptotic, autophagic, signalling and inflammatory proteins
(continued).
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Figure 50: High glucose/high palmitic acid treatment-induced alterations in the
expression of apoptotic, autophagic, signalling and inflammatory proteins
(continued).
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3.4.11 Treatment with L-glucose as an osmotic control
To confirm that the effects of high glucose concentration were not associated
with osmotic stress, which could affect cell morphology and functions, L-glucose (25
mM) was added in the current study as an osmotic control. D-glucose and L-glucose
are enantiomers, so they are the mirror image of each other. The difference between
the two structures is in the position of the -OH group on the C-chain of the molecule.
Another difference is that D-glucose is physiological and naturally occurring, while
L-glucose does not occur naturally and must be synthesised in the laboratory. The
reason for using L-glucose as an osmotic control is that L-glucose cannot be
absorbed by GLUT receptors and hence cannot be phosphorylated by hexokinase, the
first enzyme in the glycolysis pathway, so it will stay outside the cells. As shown in
Figure 51 (A, B, C,) there is no effect of added L-glucose on oxidative stress,
suggesting
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Figure 51: Treatment with L-glucose as an osmotic control.
L-glucose was used to exclude the osmotic effect of D-glucose in cell function. Rin5F cells were grown to confluence and treated with different concentrations of
palmitic acid. ROS production (A), LPO (B) and NO (C) production were assayed as
performed with D-glucose and as described in Material and Methods. Results are
expressed as mean +/- SEM of three experiments. Asterisks indicate significant
differences (*p≤0.05, **p ≤0.01, ***p ≤0.001) relative to untreated control cells
under normal glucose condition, triangles indicate significant differences (ΔΔp
≤0.01, ΔΔΔp ≤0.001) relative to untreated control cells under high glucose condition.
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3.5 The effect of NAC pre-treatment on high glucose/high palmitic acidinduced toxicity in Rin-5F cells
3.5.1 Effect of NAC pre-treatment on oxidative stress in high glucose/high
palmitic acid-treated cells

Figure 52 shows the effect of high glucose/high palmitic acid treatment with/
without NAC, (10 mM), on ROS production in Rin-5F cells. As observed before,
immunofluorescent microscopic studies showed a significant increase in ROS
production with increasing concentrations of palmitic acid, which was markedly
reduced in the presence of NAC (Figure 52A). Intracellular ROS production was also
measured fluorometrically and by flow cytometry using FACSDiva software, as
shown in Figure 52B and 52C, respectively. A remarkable decrease in ROS
production was observed with NAC pre-treatment (~ 20% and 25%) when measured
fluorometrically and almost 15-20% when measured by flow cytometry.
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Figure 52: NAC pre-treatment-reduced ROS production in high glucose/high
palmitic acid-treated Rin-5F cells.
Rin-5F cells were grown on cover slips and treated with different concentrations of
palmitic acid. Intracellular ROS production was measured using the probe, DCFDA.
The fluorescence staining was captured microscopically (A), measured
fluorometrically (B) and measured by flow cytometry (C). NAC pre-treatment to
high glucose/high palmitic acid resulted in marked reduction in ROS production.
Results are expressed as mean +/- SEM of three experiments. Asterisks indicate
significant differences (*p≤0.05) relative to untreated control cells under normal
glucose condition, triangles indicate significant differences (ΔΔΔp ≤0.001) relative
to untreated control cells under high glucose conditions, (€ p≤0.05) relative to 0.06
mM palmitic acid in the presence of high glucose, (○ p≤0.05) relative to 0.3 mM
palmitic acid in the presence of high glucose.
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Figure 52: NAC pre-treatment-reduced ROS production in high glucose/high
palmitic acid-treated Rin-5F cells (continued).

133
As shown in Figure 53A, NAC pre-treatment caused a remarkable reduction in
NO production. Almost a 25% reduction was observed after NAC pre-treatment with
both 0.06- and 0.3-mM palmitic acid in the presence of high glucose. Similarly, NAC
treatment also caused a significant reduction in LPO (~40% reduction) with both
0.06- and 0.3-mM palmitic acid treatment in high glucose (Figure 53B).
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Figure 53: Effect of NAC on NO production and LPO in high glucose/high palmitic
acid-induced toxicity in Rin-5F cells.
Rin-5F cells were cultured to 70-80% confluence and treated with different
concentrations of palmitic acid. NO production was determined by measuring the
concentration of total nitrite in the culture supernatants (A) and LPO was measured
as total amount of malonedialdehyde (B) as per the vendor’s protocol. Results are
expressed as mean +/- SEM of three experiments. Asterisks indicate significant
differences (ΔΔp ≤0.01, ΔΔΔp ≤0.001) relative to untreated control cells under high
glucose condition, (€ p≤0.05) relative to 0.06 mM palmitic acid in the presence of
high glucose, (○ p≤0.05) relative to 0.3 mM palmitic acid in the presence of high
glucose.
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As shown in Figure 54, NAC treatment prior to high glucose/ high palmitic
acid treatment resulted in a marked reduction in total NADPH oxidase (NOX)
activity (A). Similarly, the recovery effect of NAC resulted in a marked reduction in
mitochondrial NOX almost to control levels (B).

Figure 54: Effect of NAC on the activity of NADPH oxidase (NOX) enzyme in high
glucose/high palmitic acid-treated cell.
Rin-5F cells were grown to 70-80% confluence and treated with different
concentrations of palmitic acid for 24h. NOX activity was measured using the
lucigenin‐enhanced chemiluminescence method using the Turner Designs TD‐20/20
luminometer as described in Materials and Methods. Total activity of NOX (A) and
mitochondrial NOX activity (B) were measured. Results are expressed as mean +/SEM of three experiments. Asterisks indicate significant differences (ΔΔp ≤0.01,
ΔΔΔp ≤0.001) relative to untreated control cells under high glucose condition,
(€€p≤0.01) relative to 0.06 mM palmitic acid in the presence of high glucose, (○
p≤0.05, ○○p≤0.01) relative to 0.3 mM palmitic acid in the presence of high glucose.

136
3.5.2 Effect of NAC pre-treatment on SOD and catalase enzyme activities in
high glucose/high palmitic acid-treated cells
NAC pre-treatment significantly reduced the activity of SOD (almost 50%)
which was increased with 0.3 mM palmitic acid treatment in the presence of high
glucose. However, not much effect was observed with 0.06 mM palmitic acid (Figure
55A).
NAC pre-treatment also caused a mild decrease in the catalase activity, which
increased with palmitic acid in the presence of high glucose (Figure 55B). These
results suggest that the cells were under reduced oxidative stress conditions in the
presence of NAC, and there was a reduction in the concentration of ROS
metabolising enzymes due to reduced ROS production in NAC-treated cells.
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Figure 55: Effect of NAC pre-treatment on SOD and catalase activities in high
glucose/high palmitic acid-treated Rin-5F cells.
Rin-5F cells were grown to 70-80% confluence and treated with different
concentrations of palmitic acid with/without NAC. Prior treatment with NAC to 0.3
mM palmitic acid caused a significant reduction in SOD (A) as well as in catalase
(B). SOD was measured as percentage conversion of NBT to NBT-diformazan
according to the vendor’s protocol. Catalase measurement (B) was dependent on its
ability to catalyse the oxidation of alcohol such as methanol by hydrogen peroxide,
and the produced formaldehyde was measured colorimetrically. Results are
expressed as mean +/- SEM of three experiments. Asterisks indicate significant
difference (*p≤0.05) relative to untreated control cells under normal glucose
condition, (Δp≤0.05, ΔΔp ≤0.01) relative to untreated control cells under high
glucose condition, (○ p≤0.05, ○○p≤0.01) relative to 0.3 mM palmitic acid in the
presence of high glucose.
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3.5.3 Effect of NAC pre-treatment on mitochondrial bioenergetics in high
glucose/high palmitic acid-treated cells
3.5.3.1 Mitochondrial activity
As shown in Figure 56A and B, a significant recovery of complex I and IV
activity was observed with NAC pre-treatment when Rin-5F cells were treated with
palmitic acid in the presence of high glucose. The recovery effect was more
predominant with 0.3 mM palmitic acid.
3.5.3.2 ATP production
Palmitic acid caused a significant reduction in ATP production in the presence
of high glucose. NAC pre-treatment caused a moderate increase in ATP production
with 0.3 mM palmitic acid. However, with 0.06 mM palmitic acid a decrease in ATP
production was observed (Figure 56C).
3.5.3.3 Mitochondrial membrane potential
A significant loss of membrane potential was observed with palmitic acid
treatments in the presence of high glucose. NAC pre-treatment reduced the
percentage loss of potential by ~ 8 % and 26 % with 0.06 and 0.3 mM palmitic acid,
respectively (Figure 56D).
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Figure 56: Effect of NAC pre-treatment on mitochondrial functions in high
glucose/high palmitic acid-treated Rin-5F cells.
Respiratory complex I (A) and complex IV (B) were measured using their respective
substrates. ATP content (C) was measured using the ATP Bioluminescent somatic
cell assay kit. Mitochondrial membrane potential (Δψm) was measured by flow
cytometry using a fluorescent cationic dye according to the vendor’s protocol (D). A
typical histogram representing the percentage loss of mitochondrial membrane
potential is shown. Results are expressed as mean +/- SEM of three experiments.
Asterisks indicate significant differences (*p≤0.05) relative to untreated control cells
under normal glucose condition, (Δp≤0.05, ΔΔp ≤0.01) relative to untreated control
cells under high glucose conditions, (€ p≤0.05) relative to 0.06 mM palmitic acid in
the presence of high glucose, (○ p≤0.05, ○○p≤0.01,○○○p≤0.001) relative to 0.3 mM
palmitic acid in the presence of high glucose.

140

Figure 56: Effect of NAC pre-treatment on mitochondrial functions in high
glucose/high palmitic acid-treated Rin-5F cells (continued).
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3.5.4 Effect of NAC pre-treatment on apoptosis in high glucose/high palmitic
acid-treated cells
3.5.4.1 DNA fragmentation and Hoechst staining
As shown in Figure 57A and B, increased DNA fragmentation and nuclear
condensation were observed with palmitic acid treatment, especially with 0.3 mM
palmitic acid in the presence of high glucose. NAC pre-treatment, however, caused a
substantial protection against the apoptotic effect of palmitic acid treatment under
high glucose conditions.
3.5.4.2 Flow cytometry
Figure 57C shows there was a significant increase in apoptotic cell death with
0.06 mM palmitic acid which further increased with 0.3 mM palmitic acid. NAC pretreatment, however, caused only moderate reduction in the percentage of cells
undergoing early/late apoptosis, suggesting a protective effect of NAC against high
glucose/high palmitic acid-induced toxicity.
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Figure 57:Effect of NAC pre-treatment on apoptosis in high glucose/high palmitic
acid-treated cells.
DNA fragmentation was analysed by agarose gel (2%) electrophoresis and ethidium
bromide staining (A). Staining of fragmented nuclei of treated cells was performed
using Hoechst33342 dye (B). Cells with signs of apoptosis showed fragmented
nuclei. Apoptosis was measured by flow cytometry (C) using FACSDiva software.
Representative dot plots are shown and percentage of apoptotic cells is represented
as a histogram. Results are expressed as mean +/- SEM of three experiments.

143

Figure 57: Effect of NAC pre-treatment on apoptosis in high glucose/high palmitic
acid-treated cells (continued).
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Figure 57: Effect of NAC pre-treatment on apoptosis in high glucose/high palmitic
acid-treated cells (continued).
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3.5.5 Effect of NAC pre-treatment on GSH metabolism in high glucose/high
palmitic acid-treated cells

Since NAC is a glutathione precursor, the effect of NAC pre-treatment on
glutathione level was studied, by measuring the ratio of reduced GSH to oxidised
GSSG, in pancreatic cells treated with high glucose/high palmitic acid. As shown in
Figure 58, a significant reduction in GSH/GSSG ratio was observed after high
glucose/high palmitic acid treatment. NAC pre-treatment markedly enhanced the
GSH/GSSG ratio by 20% and 50% after 0.06- and 0.3-mM palmitic treatment,
respectively.

Figure 58: Effect of NAC pre-treatment on GSH metabolism in high glucose/high
palmitic acid-treated Rin-5F cells.
GSH/GSSG ratio was measured using a GSH/GSSG-Glo kit as described in the
Materials and Methods. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (*p≤0.05) relative to untreated
control cells under normal glucose conditions, (ΔΔp ≤0.01, ΔΔΔp ≤0.001) relative to
untreated control cells under high glucose condition, (€ p≤0.05) relative to 0.06 mM
palmitic acid in the presence of high glucose, (○○p≤0.01) relative to 0.3 mM palmitic
acid in the presence of high glucose.
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3.5.6 Effect of NAC pre-treatment on energy metabolism enzyme activities in
high glucose/high palmitic acid-treated cells
As shown in Figure 59, NAC pre-treatment markedly increased the activity of
HK in the presence of high glucose/high palmitic acid.

Figure 59: Effect of NAC pre-treatment on the activity of hexokinase enzymes in
high glucose/high palmitic acid-treated Rin-5F cells.
Hexokinase activity was measured by a coupled enzyme assay method as mentioned
in the Materials and Methods. Results are expressed as mean +/- SEM of three
experiments. Asterisks indicate significant differences (Δp≤0.05) relative to
untreated control cells under high glucose conditions, (€ p≤0.05) relative to 0.06 mM
palmitic acid in the presence of high glucose, (○ p≤0.05) relative to 0.3 mM palmitic
acid in the presence of high glucose.
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3.5.7 Effect of NAC pre-treatment on TNF-α release in high glucose/high
palmitic acid-treated cells
As shown in Figure 60, TNF-α was significantly increased after treatment with
0.06 mM palmitic acid in the presence of high glucose. However, no significant
alterations in TNF-α production were observed after NAC pre-treatment.

Figure 60: Effect of NAC pre-treatment on the release of TNFα in high glucose/high
palmitic acid-treated Rin-5F cells.
TNF-α was measured using standard ELISA kits as described earlier in Materials and
Methods. Results are expressed as mean +/- SEM of three experiments. Triangles
indicate significant difference (ΔΔΔp ≤0.001) relative to untreated control cells
under high glucose conditions.
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3.5.8 Effect of NAC pre-treatment on the expression of oxidative, apoptotic and
cell signalling markers in high glucose/high palmitic acid-treated cells

NAC pre-treatment increased the level of mitochondrial cytochrome c content,
indicating its effect of preserving mitochondrial integrity. However, it did not show
any protection effect on the apoptosis as expressed by cleavage of caspase-3 (Figure
61A).
On the other hand, NAC caused a remarkable recovery of the autophagic
process by reserving the inhibition of expression of LC3 II induced by high
glucose/high palmitic acid, accompanied by a decrease in phosphorylation of mTOR,
the autophagic inhibitor (Figure 61B).
Similarly, NAC pre-treatment recovered the energy homeostasis by blocking
the inhibition of AMPK phosphorylation (Figure 61C).
These results suggest that in the presence of NAC cells are protected from the
apoptotic triggers by activating autophagic self-recovery adaptation processes as well
as by preserving mitochondrial bioenergetics and redox homeostasis.
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Figure 61: Effect of NAC pre-treatment on the expression of apoptotic, autophagic
and cell signalling markers in high glucose/high palmitic acid-treated Rin-5F cells.
Total extracts (30 µg protein) from treated cells were separated on 12% SDS-PAGE
and transferred on to nitrocellulose paper by Western blotting. Mito cytc and caspase
3 (A) LC3, mTOR and AMPK (B) proteins were detected using specific antibodies
against these proteins. Beta-actin was used as loading control. The quantitation of the
protein bands is expressed as relative ratios normalised against actin or other specific
proteins as appropriate. The figures are representative of three experiments. Asterisks
indicate significant differences (*p≤0.05) relative to untreated control cells under
normal glucose conditions, (Δp≤0.05) relative to untreated control cells under high
glucose conditions, (€ p≤0.05) relative to 0.06 mM palmitic acid in the presence of
high glucose, (○ p≤0.05) relative to 0.3 mM palmitic acid in the presence of high
glucose.
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Figure 61: Effect of NAC pre-treatment on the expression of apoptotic, autophagic
and cell signalling markers in high glucose/high palmitic acid-treated Rin-5F cells
(continued).
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Chapter 4: Discussion

4.1 STZ induced cytotoxicity in Rin-5F cells and protection by NAC
treatment
Pancreatic β-cell cytotoxicity has been observed even at therapeutic
concentrations (up to 15 mM) of STZ when used as an antineoplastic drug for
different types of cancer, and this level of STZ concentration induces apoptosis in
pancreatic β-cells [117,124,241,242]. Recent studies have shown that STZ is also
toxic to neuroendocrine cells of the gut [243] as well as other GLUT 2 expressing
organs such as kidney, liver and brain [244]. It has been reported that a single
intracerebroventricular STZ injection chronically decreases glucose uptake and
produces effects that resemble features of Alzheimer’s disease [244]. Since the
cellular uptake of STZ competes with glucose uptake and is considered to be
dependent upon the specific expression of selective Glut transporters [245,246], the
differential cytotoxicity of STZ in different cellular systems may be associated with
the selective uptake of STZ, its metabolic activation and detoxification in specific
cell types as well as with the redox homeostasis and mitochondrial bioenergetics in
these cells [128,247]. We have previously demonstrated that STZ induces oxidative
stress and mitochondrial respiratory dysfunction not only in the pancreas but also in
the liver, kidney and other organs [138,248]. We have also shown that offspring born
to STZ-treated diabetic mother rats also exhibit oxidative stress-associated
complications in different organs [139]. We have previously reported STZ-induced
apoptotic cell death, oxidative stress and mitochondrial dysfunction in HepG2 cells
[140]. Oxidative/nitrosative stress and alterations in mitochondrial function and NFkB-dependent apoptosis were also reported when HepG2 cells were treated with STZ
[140].
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The present study was further extended to elucidate the mechanism of STZinduced oxidative stress, alterations in respiratory function and identification of
apoptotic markers in Rin-5F cells treated at different concentration and time points.
The selection of time points and concentrations of STZ was based on the alterations
in cell viability and morphology (as shown in figure 1A and B) and on our previous
studies on HepG2 cells, where treatment at lower concentrations for short time
periods had minimum effects on cell viability [140]. The present results on STZtreated Rin-5F cells clearly indicate increased ROS/RNS production, increased lipid
peroxidation, increased expression of oxidative stress marker protein NOS-2,
inhibition of GSH synthesis and alteration in GSH metabolism by GST and GSH–Px.
Increased activities of GST and GSH-Px suggest that STZ-induced oxidative stress
triggers the activation of antioxidant defensive mechanisms to protect beta cells from
death. We have also observed marked activation of CYP1A2 activity and moderate
activation of CYP1A1 activity in STZ-treated Rin-5F cells, probably suggesting the
metabolism of STZ by the arylhydrocarbon receptor (Ahr)-activated CYP1 enzymes.
We have previously reported increased expression of CYP isoenzymes in STZtreated type-1 and type-2 diabetic models [139,165,172,249]. However, decreased
expression of the antioxidant- responsive protein, Nrf2, was observed after STZ
treatment; it decreased drastically after 48h.

Pancreatic cells contain very low levels of antioxidant enzymes, thus these
cells are particularly sensitive to oxidative stress [250]. Nrf2 is considered a master
regulator of the antioxidant response and decreased expression of Nrf2 by STZ has
been shown by several researchers [251,252]. The reason for this loss of Nrf2
expression in pancreatic cells could be due to the STZ-induced increased intracellular
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ROS and oxidised-to-reduced GSH ratio, which has been reported in this study as
well as by other researchers. Glutathione transferase (GST) is a detoxifying enzyme
that plays a protective role against oxidative stress. The induction of this family of
enzymes is thought to be an adaptive response to chemical toxicity and oxidative
stress within cells.
In addition to Nrf2, GST induction is under the regulation of the “AhR gene
battery” as well as other transcription factors that are activated during chemical
detoxification and oxidative stress with increased ROS production. Reports also
suggest that the induction of AhR-regulated enzymes, CYP1A1 and 1A2, by
xenobiotics also induces various forms of GSTs for their metabolic detoxifications
[253–255]. Our present study also demonstrates that the activities of both
CYP1A1/1A2 as well as GST enzymes are activated after STZ treatment in Rin-5F
cells, suggesting the involvement of AhR-dependent activation of CYP1A1/1A2 and
GSTs. It has been shown that Nrf2 protein upregulates the anti-apoptotic protein,
Bcl-2, along with a battery of other cytoprotective proteins and enzymes and
prevents cellular apoptosis [256]. In our study, we observed a concentrationdependent decrease in Bcl-2 expression with a concomitant increase in pro-apoptotic
protein, Bax and increased cleavage of caspase-3. This could be due to the reduced
expression of Nrf2 protein. A concentration-dependent increase in PARP cleavage
was also observed, which supported our observation on fragmentation of DNA at
high concentrations.

Like HepG2 cells [140], the STZ-treated Rin-5F cells also exhibited
mitochondrial dysfunction followed by apoptosis. Activities of mitochondrial
respiratory enzymes Complex I, Complex II/III and Complex IV were significantly
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inhibited, though the inhibition of Complex IV was more pronounced than the other
complexes, as some recovery in the enzyme activity was seen when cells were
treated with 1 mM STZ for 48 h. As expected under these conditions, the amount of
ATP was also reduced in STZ-treated cells in a concentration- and time-dependent
manner. Increased oxidative stress and mitochondrial dysfunction resulted in
increased apoptosis in STZ-treated Rin-5F cells. More apoptotic cell death was
observed with high concentration of STZ (10 mM) for longer duration (48 h)
compared with 1 mM STZ for 24 h (Figures 4 and 5). DNA fragmentation and
activation of caspases 3 and 9 confirmed the increased apoptosis after STZ treatment.
Thus, the decrease in mitochondrial ATP synthesis and inhibition of respiratory
enzymes, increased ROS/RNS production, lipid peroxidation, DNA fragmentation
and apoptosis have further confirmed and supported our previous studies as well as
numerous other reports on the mechanism of STZ-induced cytotoxicity, in various in
vivo and in vitro models, particularly in insulin-secreting pancreatic Rin-5F cells
[128,139,140,257–259].
Furthermore, our present study has also identified the increased expression of
molecular oxidative stress and apoptotic markers such as NOS-2, as well as cleavage
of caspase-3 and PARP, in STZ-treated Rin-5F cells. The present study also shows
that STZ increases the phosphorylation of prosurvival protein Akt, suggesting that
Akt a role in altering insulin-signalling and GLUT expression. It is possible that
STZ stimulates Akt phosphorylation in Rin-5F cells to increase GLUT2 transport to
the membrane for the transport of STZ itself and to protect the cells from further
oxidative/metabolic insult. Some studies have reported a co-relation between Akt
phosphorylation and GLUT2 expression and translocation. These reports suggest that
expression and membrane translocation of GLUT2 are substantially reduced in Akt
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knockout mice [260]. Our study has also confirmed increased GLUT2 expression
with increased Akt phosphorylation at high concentrations of STZ treatment.
Our results also support the previously reported observation that STZ induces
cell resistance in β-cells towards its own toxicity. One explanation for this could be
that, in addition to the other mechanisms as reported, the STZ-treated cell might be
activating the pro-survival signals (e.g. Akt, as observed in this study) and increasing
GLUT2 levels, thus modulating glucose uptake and metabolism. Another reason
could be the increased GST/GSH-Px-dependent detoxification processes in β-cells in
order to defend cells from the deleterious effects of STZ and ROS [261,262]. The
altered expression of redox-sensitive protein, Nrf2, could also be a line of defence to
protect the cells from the cytotoxic effects of STZ. A recent study has shown that
cellular GST acts as a reservoir for NO and thus scavenges NO and detoxifies ROS
via GSH conjugation [263]. This along with the increased GST/GSH-Px-dependent
efflux/detoxification of STZ could increase resistance of the cells to ROS/NO
cytotoxicity.
The therapeutic potential of antioxidants in preventing diabetes and its
complications have been suggested in numerous studies, including our own. GSH is
a master regulator of redox homeostasis. Therefore, there is growing interest in
studying the therapeutic effects of N-acetylcysteine (NAC), a pro-drug and a GSH
precursor, in the prevention of diseases characterised by increased oxidative stress,
such as diabetes [264].
In the present study, our aim was to elucidate the cytoprotective effects of
NAC on STZ-induced toxicity in Rin-5F cells. We intended to investigate the
cytoprotective mechanisms of NAC on oxidative stress, mitochondrial bioenergetics,
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GSH metabolism and apoptosis. The selection of dosage and time intervals for the
STZ treatment were based on our previous study of Rin-5F cells [238] and HepG2
[140] where lower concentrations for a short time (24h) had minimal effect on cell
viability.
A significant recovery of altered GSH metabolism by NAC treatment was
observed in STZ-treated cells, suggesting the potential mechanism of NAC action in
protecting cells from oxidative stress. NAC has also been shown to exert its
antioxidant and anticancer effects by modulating glutathione metabolism and the
biotransformation of carcinogenic substances in vivo [265].
Studies have shown that glutamate dehydrogenase plays a key role in
regulating redox homeostasis through the activation of GSH-Px [266]. In our study
we found that STZ treatment significantly decreased the activity of GSH and
increased ROS production, which might have activated the ROS scavenger enzyme,
GSH-Px, to regulate the redox homeostasis. NAC treatment significantly decreased
the amounts of ROS, subsequently reducing the activity of GSH-Px.
Endogenous ROS production plays an important role in the regulation of
glycolytic activity and expression of glycolytic enzymes, including HK, which could
be reversed by NAC pre-treatment [267]. Our study also indicated a similar decrease
in HK activity after NAC pre-treatment, which could be related to its antioxidant
effects.
The key parameter for evaluating mitochondrial function is mitochondrial
membrane potential, which drives the synthesis of ATP [268]. A significant loss of
potential was observed in Rin-5F cells after treatment with STZ accompanied by a
decrease in the activities of the respiratory complexes, Complex I and Complex IV,
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as well as that of the mitochondrial matrix enzyme, aconitase. NAC treatment
significantly recovered the membrane potential and the activity of ROS-sensitive
aconitase enzyme. However, NAC treatment inhibited the activity of Complex I but
not Complex IV. This could be because NAC acts as a redox sensor by inhibiting
Complex I activity and limiting the oxygen and NADH utilization, thus reducing
oxidative stress [269]. Complex I may also be inhibited by excess GSH through
glutathionylation [270], since NAC treatment results in an increase in GSH levels.
Moreover, the suppression of Complex I activity could also be a result of Snitrosation of Complex I by NO, which is an effective mechanism to prevent ROS
formation, thus protecting the cells from oxidative stress [271,272]. We have
previously shown that NAC treatment partially protects the oxidative modification of
mitochondrial complexes and helps in preserving the mitochondrial function in
HepG2 cells [273]. Studies have also shown membrane permeabilisation to be
related to apoptosis [274]. Our present study has also demonstrated activation of
caspase-3, caspase-9 and an increased ratio of Bax/Bcl-2 expression. This confirms
the increased oxidative stress and thus the increased apoptosis after STZ treatment,
which recovered significantly after NAC pre-treatment.
Another important finding of our study was the marked reduction in insulin
secretion, which, however, is not normalized by NAC pre-treatment. This could be
due to NAC scavenging the ROS, physiologically required for insulin secretion.
However, a moderate increase in insulin secretion was observed in cells treated with
NAC alone. This could be due to the improvement of pancreatic physiological and
mitochondrial functions, which control the glucose-stimulated insulin secretion. This
is supported by previous studies suggesting that the improvement of insulin secretion
by NAC treatment is associated with improvement of GLUT 2 expression and insulin
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synthesis [199,275]. However, in the long-run, the regeneration of beta cells and
preservation of the physiology and mitochondrial bioenergetics in pancreatic cells,
along with the scavenging of ROS and stimulation of antioxidant defence
mechanisms by NAC, may improve insulin synthesis and secretion in the damaged
beta cells.
GDH also plays a key role in insulin secretion [276]. Studies have shown that
overexpression of GDH enhances insulin secretion, whereas deletion of GDH
significantly reduces insulin secretion in pancreatic cells [277,278]. In the present
study, we have found that NAC pre-treatment does not significantly recover the
GDH activity, which could be the reason for the decreased insulin secretion observed
in these cells.

4.2 High glucose/high palmitic acid treatment-induced cytotoxicity in Rin5F cells and protection by NAC treatment
Energy production results mainly from the oxidative metabolism of glucose
and fatty acids, which are interlinked by a central pathway, called the glycerolipid/
free fatty acid cycle (GL/FFA cycle). They contribute significantly to tissue building
and are involved in disease development, particularly of metabolic diseases and
cancer [1–5]. The specific pathogenesis of these diseases remains unclear. However,
the deleterious effects of the chronic elevation of glucose and fatty acid levels have
been shown to have a significant role. Several hypotheses have been proposed,
including glucotoxicity and lipotoxicity [2,4,6,7]; caused by chronic hyperglycaemia
and chronic dyslipidaemia, respectively. The concept of glucolipotoxicity has arisen
from the combination of the deleterious effects of the chronic elevation of glucose
and fatty acid levels on pancreatic β-cell function and/or survival [27]. The
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synergistic effect of the combination of both nutrients exacerbates β-cell dysfunction
over time and creates a vicious cycle by which the impairment of insulin secretion
worsens the metabolic disturbances [27,28]. Studies have shown that elevated
glucose levels augment the effect of FFA-induced cell death, because high glucose
inhibits fat oxidation, and consequently lipid detoxification [22]. This can be
explained by the interplay between glucose and fatty acids, whereby elevated glucose
concentration increases the formation of malonyl-CoA which subsequently inhibits
the mitochondrial fatty acid transporter (CPT1), decreases the fatty acid oxidation
[279] and further promotes the fatty acid esterification to lipids [280] which
consequently impair β-cell function and mass [7]. Earlier it was hypothesised that
chronic exposure to FFAs could result in the inhibition of glucose-induced-insulin
secretion in a Randle-like effect [281,282]. The inhibition of insulin secretion is
coupled with diminished glucose oxidation, suggesting the reciprocal relation
between the glucose and fatty acid metabolism. The Randle cycle (the glucose-fatty
acid cycle), first proposed in 1963 by Philip Randle and his group [281], involves
substrate competition between the end-products of fatty acid β-oxidation and
glycolysis in the mitochondrial matrix to enter the citric acid cycle for further
oxidation. The Randle cycle expresses the energetic interaction between glucose and
lipid substrates, which is at variance with the metabolic ‘citric acid cycle’, in which a
series of chemical reactions occur in a cycle [283]. The Randle cycle highlights the
competition between glucose and fatty acids for their oxidation in muscle and
adipose tissue, but similar observations were found in pancreatic β-cells [284], in
which long-term intralipid perfusion in rat caused an inhibition of glucose-inducedinsulin secretion. Glucose metabolism is the determining factor of glucose-inducedinsulin release [285] in pancreatic β-cells. Accordingly, to observe the Randle effect,
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we would assume that glucose-induced insulin release is diminished in favour of
fatty acid oxidation when the concentration of fatty acid is elevated. However, such
results have not been observed either experimentally or clinically; in contrast,
numerous studies suggest that fatty acid stimulates insulin releases [286–288].
The definite mechanism of glucolipotoxicity in pancreatic β-cells is a subject
of debate and the conclusion still needs to be established. Moreover, it is not clearly
understood how pancreatic cells handle excess fuel and what the subsequent fate of
the cells is to avoid toxicity. Therefore, our aim was to elucidate the cytotoxic
mechanisms of high glucose/ high palmitic acid treatment in insulin-secreting Rin-5F
cells with the focus on: oxidative stress; mitochondrial bioenergetics; redox
metabolism and homeostasis; cell signalling and inflammatory responses; and the
mechanisms of cell death (apoptosis, necrosis). Furthermore, we aimed to study the
cytoprotective effects of NAC, an antioxidant, on the toxicity induced by high
glucose/ high palmitic acid in Rin-5F cells.
In this study, we hypothesize that the deleterious effects of glucolipotoxicity in
pancreatic β-cells depend on fatty acid concentration and are augmented in the
presence of high glucose. Therefore, we studied the effects of different
concentrations of palmitic acid under normal and high glucose conditions in
pancreatic β-cells. The reason we selected pancreatic cells was because the pancreas
is a centralized organ that metabolically controls almost the entire body by
orchestrating the secretion of the endocrine hormones (especially insulin) in response
to nutrients (glucose, lipids and amino acids), as well as via inflammatory signals.
Pancreatic β-cells are a primary nutrient sensor in the human body. Therefore , we
proposed to use an in vitro cellular model, Rin-5F insulin secreting pancreatic cells,
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to study the effects of high glucose and high fatty acids alone or in combination
(glucolipotoxicity) to target the molecular/biochemical markers directly and at the
same time to avoid interference by other factors: physiological, physical, endocrine,
dietary and environmental, which work in tandem in disease progression. Cells were
treated with high glucose (25 mM) and high saturated fatty acid, palmitic acid (up to
0.3 mM). These concentrations were based on literature searches and our preliminary
assays on cell viability/survival. The human physiological range for plasma glucose
is 5.5–6 mmol/L with a maximum of ∼9 mmol/L postprandially [207,208].
Similarly, the physiological range of plasma fatty acids is 0.3 mmol/L to 4 mmol/L
[206]. Palmitic acid was chosen because it is the most abundant saturated fatty acid
[289] and a precursor of many other fatty acids in vivo, and has been reported to
exert most of the toxic effects in dyslipidaemia when compared to other saturated
fatty acids. Moreover, clinically it has been shown that the level of palmitate in
plasma increases 1.5- and 3-fold in type-2 diabetic patients during nocturnal and
postprandial states, respectively, compared with a healthy patient [290].
Our results, consistent with other studies [291,292], show that exposure of Rin5F cells to palmitic acid increased oxidative stress in a concentration-dependent
manner under high glucose condition. This finding is confirmed by an increase in
ROS/RNS production, increase in lipid peroxidation, inhibition in GSH/GSSG ratio
and alterations in GSH metabolism by GSH-reductase and GSH-Px.
The decrease in the activities of GSH-reductase and GSH-Px could have
triggered the activation of the antioxidant enzymes SOD and catalase. This could
indicate that the cells are trying to respond adaptively against the glucose/palmitic
acid toxicity due to increased ROS production. The competency of the cells to resist
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oxidative damage is determined by the effect of a battery of physiological
antioxidants, among which GSH is the most abundant. Antioxidant deficiencies
could develop as a consequence of either decreased synthesis or increased utilisation
[293]. Both cases can be explained by a decline in the reduced-to-oxidised GSH
ratio. In our study, we observed a significant inhibition of both the recycling enzyme,
GSH-reductase, as well as the detoxifying and scavenging enzyme, GSH-Px. It has
been well established experimentally and clinically that the GSH level is decreased
in diabetes. Moreover, GSH deficiency has substantial implications in the
pathogenesis of diabetic complications [294–296]. A clinical study has also shown
that dietary supplementation of GSH precursors (glycine and glutamine) can restore
GSH synthesis and lower the oxidative stress in uncontrolled diabetic patients [294].
Similarly, we have observed a significant increase in the GSH/GSSG ratio in high
glucose/high palmitic acid-treated Rin-5F cells that have been pre-treated with 10
mM NAC for 2h. This resulted in a reduction of oxidative stress in the cells, as
observed by a decrease in ROS/RNS production, decreased LPO and even a decline
in the antioxidant activity (SOD). This may explain the consequential equilibrium of
the redox status provided by NAC that does not require the effects of multiple
antioxidant enzymes.
Mitochondria, known as the powerhouse of the cell, form the major regulator
of cellular energy metabolism. They are the main site for the metabolic oxidation of
glucose, fatty acids and amino acids into ATP. Also, they are the major source of
ROS, a by-product of the mitochondrial electron transport chain. Fatty acid has a
complex dual role in mitochondrial energy coupling. On the one hand, being a
respiratory substrate, it transfers the electrons and improves the mitochondrial energy
production. On the other hand, fatty acid is a well-known uncoupling agent for
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oxidative phosphorylation by increasing the proton conductance affecting the inner
mitochondrial membrane potential and causing energy dissipation. In the present
study, we have found that under normal glucose conditions, palmitic acid causes a
marginal increase in the activities of the mitochondrial respiratory enzymes, complex
I, II/III and IV, in a concentration-dependent manner. This effect is accompanied by
a decrease in ATP production, which explains the uncoupling effect of palmitic acid.
A similar study showed that increasing concentration of palmitic acid conversely
correlated with ATP production, after palmitate exposure for 24 h in liver cells [291].
Under high glucose conditions, palmitic acid inhibited the activities of the
mitochondrial complexes combined with a decrease in ATP production. This could
be due to the dampening effect of glucose, which was also observed by Barlow and
his colleagues [297]. They found that exposure of INS-1E cells to palmitate at high
glucose concentration reduced mitochondrial respiration and lowered the respiratory
coupling efficiency of the cells.
The coupling efficiency of oxidative phosphorylation is defined as the
proportion of mitochondrial respiration linked to ATP synthesis [298]. The
disturbance of mitochondrial energy coupling by lipids has been known since the
1950s [299]. It has been shown that fatty acids affect the mitochondrial inner
membrane by inducing proton permeability, leading to the dissipation of the
electrochemical proton gradient. This observation has been confirmed in our study.
We have observed an increased percentage loss of mitochondrial membrane potential
with increasing palmitate concentrations under both normal and high glucose
conditions, indicating an increase in membrane depolarisation. Furthermore,
consistent with our findings, other researchers have shown an increase in oxidative
stress and increase in mitochondrial membrane depolarisation, accompanied by a
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decrease in ATP content and glucose-stimulated insulin secretion in pancreatic βcells, Rin-5F and HIT-T15 under high glucose and high fatty acid conditions [300].
However, unlike our observations, they found an increase in the activities of
the mitochondrial respiratory complexes under high glucose/high fatty acid
conditions. This discrepancy may be due to the mechanism of action of the product
used to induce lipotoxicity in the two studies. They used a product TO901317, a
potent and selective agonist for liver X receptor (LXR), which has minimal effect on
the mitochondria. It has been reported that chronic activation of LXR under high
glucose conditions contributes to lipotoxicity-induced beta-cell dysfunction [301].
The present study used palmitate, which competes with glucose for oxidative
metabolism in mitochondria. This may explain the inhibitory effect of palmitate on
the mitochondrial respiratory activities in the presence of high glucose concentration.
The depolarization of the mitochondrial inner membrane promotes the opening
of the permeability transition pore (PTP) [302], causes release of apoptotic proteins
from the mitochondria to the cytosol, promotes the activation of apoptotic cascade
[303] and eventually causes cell death. In the present study, palmitic acid under both
normal and high glucose conditions increases the activities of caspase-9 and -3 in a
concentration-dependent manner, accompanied by an increase in the proapoptotic to
antiapoptotic ratio (Bax/Bcl-2), and a decrease in oxidised mitochondrial cytochrome
c. Also, an increase in PARP cleavage was observed with high concentration of
palmitic acid, which supported the proposed DNA fragmentation.
Moreover, our results demonstrate the roles of palmitic acid-induced
mitochondrial ROS through a significant reduction of the mitochondrial sensitive
enzyme aconitase, with pronounced effect under normal glucose rather than high
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glucose conditions. Also, an increase in mitochondrial NOX has been observed,
consistent with a decrease in mitochondrial membrane potential and ATP production.
The deterioration of mitochondrial function is followed by the release of cytochrome
c and the activation of the caspase-dependent apoptosis pathway. Furthermore, we
have found that NAC pre-treatment partially conserves the mitochondrial
bioenergetics. It can maintain the mitochondrial membrane potential, increase the
activities of complex I and IV and partially reserve the ATP production. NAC also
causes a significant reduction in the mitochondrial NOX. Moreover, NAC attenuated
the DNA fragmentation and diminished the high glucose/high palmitic acid-induced
apoptosis.
Autophagy is a mechanism conserved through evolution. It serves as a
recycling system in which cells degrade aged and damaged organelles such as
unfolded proteins [304]. This process is known to serve as a survival mechanism in
states of starvation [305] and oxidative stress [306]. Several studies reported the
autophagy dysfunction in many pathological conditions such as diabetes, cancer and
neurodegenerative diseases [307–309]. Apoptosis is down-regulated by autophagy
and apoptosis-associated caspase activation shuts off the autophagic process
[310,311].
In our study, we have found that high concentrations of palmitic acid decrease
the expression of autophagic proteins along with increased apoptosis. We considered
Atg5, the essential protein for autophagosome formation, and LC3-II, which has LC3
conjugated to phosphatidylethanolamine which is recruited to autophagosomal
membranes. Consistent with our finding, other investigators have found that glucose
and palmitic acid exposure inhibit the autophagic turnover in β-cells which leads to
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apoptotic cell death through activation of mTORC1, an inhibitor of autophagy [312].
Las and his team found that autophagic flux was reduced in β-cells treated with
palmitate and glucose with concomitant suppression of insulin release [313], as
confirmed in our study. They showed that the reduction of autophagy was related to a
palmitate suppressor effect on mitochondria bioenergetics which led to decreased
cellular ATP. Consequently, the lysosomal H+ pump capacity decreased, thus
inhibiting the fusion of lysosomes with autophagosome and eventually decreasing
autophagic flux. We hypothesise that the adaptive mechanisms (autophagy) of the
cells are overwhelmed after exposure to the high concentration of glucose and
palmitic acid, pushing the cells into the apoptotic phase. Furthermore, it has been
shown that apoptosis accompanied by caspase activation results in the cleavage of
multiple proteins including autophagic proteins, causing inactivation of the
autophagic mechanism, thus resulting in abortion of its cytoprotective action [310].
Some investigators found that palmitic acid enhanced the levels of both the
apoptotic as well as autophagic proteins [291]. Furthermore, the inhibition of
autophagy, by pharmacological inhibitors or by knockout of specific autophagic
genes, rescued the palmitic acid-induced apoptosis in endothelial cells [314]. The
conflicting results between different studies could be due to differences in the
concentration and duration of the glucose/palmitic acid treatment, the type of cells
used for the study and the ratio of BSA/palmitic acid conjugation.
Autophagy has also been correlated with JNK activation. Studies have shown
that activated JNK promotes autophagy through stimulating the expression of
autophagic related proteins ATG5, ATG7 and LC3 [315]. Similar observations were
found in our study. We found that palmitic acid caused a concentration-dependent
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inhibition of JNK phosphorylation concomitant with decreased expression of Atg5
and LC3.
It is worth mentioning that autophagy is regulated by mTORC1 and AMPK.
The mTORC1 negatively controls autophagy through phosphorylation of ATG13 and
ULK1 complex. ATG13 stabilises and activates ULK, and thereby facilitates the
phosphorylation of FIP200 by ULK [316]. Inhibition of mTORC1 leads to
dephosphorylation of ATG13 and ULK and activates ULK1 to take a ‘closed’
conformation, an active form. In the active form ULK1 may phosphorylate ATG13
and FIP200 and thus trigger the downstream autophagy process [317]. AMPK
stimulates autophagy by inhibiting mTORC1 and by phosphorylating ULK1 [318]. It
is known that nutrient overload activates mTORC1 and inhibits AMPK, and
consequentially suppresses autophagy [319,320] which is consistent with our study.
We found that NAC pre-treatment resulted in reversal of autophagic suppression by
inhibiting mTOR activation and stimulating AMPK. The stimulation of autophagy
was confirmed by an increase in the expression of autophagic protein LC3-II.
Long exposure to palmitate is known to impair GSIS [107,284,321,322],
suggesting that the mitochondrial uncoupling effect of palmitate reduces the glucosestimulated ATP production, which consequently decreases the ATP/ADP ratio in the
cytosol, inhibiting the closure of the ATP-sensitive K+ channel. This leads to
membrane polarisation, closure of voltage-gated Ca+2 channels, decrease in Ca+2
influx and eventually reduced Glut2 translocation and insulin exocytosis [323,324].
In our study, we have found that high concentration of palmitic acid decreases the
insulin level in the presence of normal and high glucose accompanied by reduced
expression of Akt phosphorylation. On the other hand, low concentration of palmitic
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acid increases the level of insulin in parallel with p-Akt expression. The explanation
could be that a low level of ROS, especially hydrogen peroxide, is an important
factor in normal cell signalling and is a potential regulator of GSIS through positive
regulation of the mitochondrial Ca+2 influx [325], enhancing the Krebs’ cycle
activity, ultimately driving insulin release [326]. It has been reported that the
incapacity of β-cells to secrete insulin in response to glucose is associated with a
decrease in ROS production [325], since pancreatic β-cells possess very low levels of
antioxidant enzymes, especially GSH-Px and catalase [327]. Excessive and sustained
ROS production can interrupt the integrity of the physiological function and decrease
insulin content. Thus, short-term activation of ROS increases GSIS, but excessive
ROS impairs insulin secretion [328,329]. Our results confirm that high concentration
of palmitic acid reduces the insulin content due to excessive ROS production, while
low concentration of palmitic acid improves the insulin level, due to low ROS
production.
Another explanation links the insulin release with mitochondrial action. Some
researchers have elucidated that the impairment of GSIS by palmitate is due to the
involvement of mitochondrial uncoupling protein UCP2 [322,330], while others
question the involvement of UCP2 in the impairment of GSIS [331]. Thus, the role
of UCP-2 in the lipotoxicity of β-cells is still controversial.
Another key player that controls insulin secretion is GDH [276]. Alterations in
the expression of this enzyme have been shown to modify the insulin secretary
response in pancreatic cells [277,278]. Similar alterations have been observed in our
study. We have found a decrease in insulin levels with concomitant decrease in GDH
activity in cells treated with palmitic acid under normal and high glucose conditions.
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GDH is considered a housekeeping enzyme, which catalyses the reversible oxidative
deamination of L-glutamate to α-ketoglutarate using NAD(P)+ as coenzyme. It is
regulated by the cell’s energy state. It is positively controlled by ADP, GDP and
some amino acids, and negatively by ATP, GTP and NADH. Thus, GTP and ADP
are considered as the main endogenous negative and positive modulators for GDH,
respectively. This allosteric interaction has been reported to control GDH activity in
response to cellular energy demands [332]. Thus, when the level of ATP is high,
conversion of glutamate to α-ketoglutarate is limited; however, when the cellular
energy status is low, GTP is activated and glutamate is converted to α-ketoglutarate
[333] stimulating the Kreb’s cycle to produce energy eventually in the form of ATP.
In our study, we have found that palmitic acid causes a decrease in ATP
production, in concentration-dependent manner. This may be a consequence of
glutamate influx inhibition, due to a decrease in GDH activity, and ultimately
diminished activity of the Kreb’s cycle. This reduction in Kreb’s cycle activity could
also be due to a reduction in the concentration of glycolytic enzymes HK and
G6PDH after treatment with palmitic acid as shown in our study. It has been reported
that exposure to high concentration of palmitic acid decreases the expression of
hexokinase and pyruvate enzymes and increases the oxidation of palmitoylcarnitine,
thus shifting the aerobic metabolism towards the oxidation of fatty acids in the
endothelial cells [334]. Furthermore, we have also found that NAC pre-treatment is
able to rescue the HK activity, which in turn might increase glycolysis.
Further, GDH function has been linked to redox homeostasis via fumarate
formation [266]. Lingtao et al. reported that suppression of GDH decreased the level
of α-ketoglutarate and fumarate, leading to reduced GSH-Px activity and
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subsequently elevated ROS that attenuated tumour growth. In parallel, our study
shows a decrease of activities of GDH as well as of the ROS scavenging enzyme,
GSH-Px, in concentration-dependent manner after palmitate treatment. This further
identifies the mechanisms of ROS production in β-cells under lipotoxicity and
glucolipotoxicity conditions.
Oxidative stress and inflammation act as cooperative and synergistic partners
in the pathophysiology of numerous diseases such as diabetes, obesity,
cardiovascular diseases, neurological disorders and cancer. Studies have shown that
palmitic acid triggers the production of pro-inflammatory cytokines and oxidants,
leading to cellular hypertrophy and apoptosis [335,336]. Fatty acids can directly
activate inflammatory pathways themselves, to potentiate inflammatory toxicity. In
our study, we have observed an increased translocation of nuclear NF-kB with
increasing palmitic acid concentrations, which in turn, might trigger the release of
pro-inflammatory cytokines such as TNF-α, IL-6 and PGE2. However, the increase
is more pronounced in the lower concentration of palmitic acid compared with the
higher concentration. A similar trend is also found with the production of NO.
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Chapter 5: Conclusion
Our study on elucidating the cytotoxicity mechanisms of the well-known
diabetogenic agent, STZ, provides additional evidence and has confirmed that the
mechanisms of STZ-induced cytotoxicity and apoptosis in Rin-5F cells is mediated
by increased oxidative/nitrosative stress, mitochondrial dysfunction and alterations in
cell signalling. In addition, our results suggest that STZ-treated Rin-5F cells induce
some cellular protection pathways as indicated by altered cell signalling and
detoxification mechanisms which might be associated with the development of
cellular resistance towards STZ. Furthermore, our results demonstrate that NAC
treatment protects the Rin-5F cells from STZ-induced toxicity via modulation of
energy and redox homeostasis and suppression of oxidative stress. The activation of
antioxidant defence mechanisms and regeneration of cellular GSH followed by the
preservation of key mitochondrial bioenergetics functions may be involved, at least
in part. Schematic models have been presented to highlight the mechanisms of STZinduced cytotoxicity (Figure 22) and the protective effects of NAC on STZ-induced
cytotoxicity in Rin-5F cells (Figure 32).
A second conclusion of the present study is that the deleterious effects of
glucolipotoxicity seem to be related to the concentration of fatty acid. The molecular
mechanism of high glucose/palmitic acid is mediated by imbalance of redox
homeostasis, disruption of mitochondrial bioenergetics and alteration of GSH
metabolism. These effects are accompanied by an inhibition of cell survival,
increased ROS/RNS production, lipid peroxidation and induction of apoptosis by
alteration of cell signalling molecules and inflammation. Furthermore, the high
glucose/high palmitic acid effect is associated with a decrease in activity of energy
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metabolism enzymes GDH and HK, along with decreased insulin levels.
Additionally, there is growing interest in studying the therapeutic effects of Nacetylcysteine (NAC) in the prevention of diseases characterised by increased
oxidative stress, such as diabetes [264]. Therefore, we extended our study to
elucidate the effects of NAC pre-treatment under high glucose/high palmitic acid
conditions. Our results show that NAC attenuates the high glucose/high palmitic
acid-induced ROS/RNS production and lipid peroxidation. GSH metabolism is
significantly recovered with NAC pre-treatment, and mitochondrial bioenergetics are
partially conserved. NAC can maintain the mitochondrial membrane potential while
increasing the activities of complex I and IV and partially reserving ATP production.
Moreover, NAC attenuates the DNA fragmentation and diminishes the high
glucose/high palmitic acid-induced apoptosis by stimulating the autophagy process.
Some of these studies have already been published in high-impact journals. We are
processing other data for further publication.
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